Clinical Study Protocol  R668 -ALG -16115 Amendment 2  
IND Number:  017987  Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
A STUDY TO EVALUATE THE EFFICACY OF DUPI LUMAB AS AN ADJUNCT FOR 
SUBCUTANEOUS GRASS I MMUNOTHERAPY TO REDU CE PROVOKED 
ALLERGIC RHINITIS SY MPTOMS USING THE NAS AL ALLERGEN 
CHALLENGE  MODEL  
Compound : REGN668 (dupilumab)  
Clinical Phase:  2a 
Protocol Number:  R668 -ALG -16115  
Protocol Version:  R668 -ALG -16115 Amendment 2  
Amendment 2 Date of Issue:  See appended electronic signature page  
Amendment 1 Date of Issue: 13 Apr 2018  
Original Date of Issue:  20 Dec 2017  
Medical/Study Director:  Associate Director  
Early Clinical Development and Experimental 
Sciences  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591  
VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00[STUDY_ID_REMOVED]

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
Regeneron Pharmaceuticals, Inc .  Page 2 of 87 
CONFIDENTIAL  Amendment 2  
The purpose of this amendment is to respond to  feedback received from the FDA . 
The following table outlines the changes made to the protocol and the affected sections:  
Change and Rationale for Change  Section Changed  
As requested by the FDA, added a secondary endpoint 
which is the “Change and percent change from baseline 
in the TNSS AUC post NAC over the first hour of the 
challenge  (0-1 hr post peak TNSS) at week 17 for 
dupilumab + SCIT as compared to dupilumab + placebo 
for SCIT.”  Clinical Study Protocol Synopsis: Objective(s)  and 
Endpoints  
Section  2.2 Secondary Objectives  
Section  4.2.2  Secondary Endpoints  
Added a footnote to clarify that the NAC happens after 
16 weeks of study treatment at week 17.  Section  5.1.1.2 , Figure  1 Study Flow diagram  
Changed text regarding the follow -up of pregnancies in 
dupilumab studies.   
The changes were made based on a decision made by 
the program team, which aligns with the current 
dupilumab label.   Section  6.2.2  Exclusion Criteria, #33  
Section  9.4.3 . Other Events that Require Accelerated 
Reporting to  Sponsor  
As requested by the FDA, added text that “The Placebo 
SCIT will have an identical appearance to the Grass 
SCIT” for clarification.  Section  7.1.2  Timothy Grass SCIT: Reference 
Treatment  
Added the following footnote to the schedule of events 
table for clarification:  
18. The visit should be conducted as close as possible 
to the designated study schedule date and the window 
for the days used only as needed.   Section  8.1.1  Footnotes for the Schedule of Events 
Table ; footnote  #18  
Added text to clarify that treatment with prohibited 
medications is allowed during the study if medically 
necessary as judged by the  investigator (ie, as needed 
for allergic symptoms related to SCIT or SCIT placebo 
or related to study procedures).   Section  7.7.1  Prohibited Medica tions (after 
Randomization) and Procedures  
Added text to clarify the grading of severity of AEs by 
Common Terminology Criteria for Adverse Events 
(CTCAE).  Section  9.5.1  Evaluation of Severity  
As requested by the FDA, corrected the type -o in the 
statistical hypothesis for superiority testing (ie, 
corrected from “week 24” to “week 17.”  Section  10.1 Statistical Hypothesis  
Minor editorial changes:  Section  8.1 Schedule of Events  
Section 10.2 Justification of Sample Size  
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
Regeneron Pharmaceuticals, Inc .  Page 3 of 87 
CONFIDENTIAL  Amendment 1 
The following table outlines the changes made to the protocol for Amendment 1 and the affected 
sections:  
Change and Rationale for Change  Section Changed  
Change the detailed description of concentrations 
delivered during the NAC (4 BAU, 10 BAU, 40 BAU, 
100 BAU, 400 BAU, 1000 BAU) to incorporate flexible 
language instead, including one highest dose, and refer 
to the Study Operations Manual for the actual dil utions 
that will be given.   
Rationale : This level of detail is better suited to the 
Study Operations Manual because we are finding during 
writing of the Study Operations Manual, that these 
doses will need to be adjusted for ease of dilution 
preparation. O ne highest dose has been suggested by 
multiple site PIs as has been done in similar studies.  Section  5.2 Screening  
Clarify that any AEs or SAEs that are related to any 
study procedure, including the NAC procedure, should 
be reported as AEs and SAEs.  
The protocol currently states “The investigator (or 
designee) will record all AEs that occur from the time 
the informed consent is signed until the end of study, 
with the exception of symptoms that occur in response 
to the NAC on the day of the NAC.  Allergic symptoms 
that occur in response to the NAC are not to be reported 
as AEs, as they will be recorded as outcome measur es”. 
The protocol now reads as follows “However, AEs that 
occur in response to the NAC that are outside of 
expected symptoms which are recorded in response to 
the NAC, or SAEs, should be reported as AEs and 
SAEs”.   
Additional text was added to Section 9.5 .2, 
“Relationship of Adverse Events to Study Procedures”  
Rationale : To clarify that reporting of AEs and SAEs 
related to study procedures.    Section  9.4.1  Adverse Events  
Section  9.5.2  Evaluation of Causality  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
Regeneron Pharmaceuticals, Inc .  Page 4 of 87 
CONFIDENTIAL  Change and Rationale for Change  Section Changed  
Correct typos and make clarifications.  
Rationale : Since the protocol has been circulated to 
study sites, we have received feedback to correct typos 
and inconsistenci es Synopsis  Added  study procedures section  
Section  3.2.7  Rationale for Primary Endpoint  
Section  3.2.8.1  Rationale of allergen -Specific IgG4 to 
IgE in Serum  
Section  3.2.8.5  Basophil Sensitivity Test for Timothy 
Grass  
Section  3.2.8.6  Frequency of Circulating Th2A Cells  
Section 3.2.8.7  Type 2 Inflammation in the Nasa l 
Mucosa in Response to a NAC as Measured by RNA 
Sequence and Gene Expression Analysis  
Section  5.2 Screening  
Section  5.3.1  Randomization  
Section  6.2.2  Exclusion Criteria, #1, #6, #8  
Table  1 SCIT Up Titration and Maintenance Regimen 
(corrected the sequence in the injection number)  
Table  2 Dosing Schedule for Dupilumab/Placebo with 
Respect to SCIT/Placebo (reference in the footnote)  
Section  7.3.2  Study Drug Discontinuation (Dupilumab 
or Placebo for Dupilumab and SCIT or Placebo for 
SCIT)  
Section  7.7 Concomitant Medicat ions and Procedures  
Table  3 Schedule of Events  
Section  8.1.1  Footnotes for the Schedule of Events  
Section  8.2.1.1  NAC and NAC Assessments:  TNSS, 
TOSS, PNIF, and Total Sneezes  
Section  8.2.1.4  Nasal Brushing  
Section  8.2.2.4  Spirometry  
Section  8.2.2.5  Peak Expiratory Flow  
Section  8.2.2.6  Laboratory Testing  
Section  9.4.2  Serious Adverse Events  
Section  9.4.3  Other Events that Require Accelerated 
Reporting to Sponsor  
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 5 of 87 
CONFIDENTIAL  TABLE OF CONTENTS  
CLINICAL STUDY PROTO COL SYNOPSIS ................................ ................................ ............. 12 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ ................ 16 
1. INTRODUCTION  ................................ ................................ ................................ ......19 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 21 
2.1. Primary Objective  ................................ ................................ ................................ .......21 
2.2. Secondary Objectives  ................................ ................................ ................................ .21 
2.3. Other Objectives  ................................ ................................ ................................ ......... 21 
3. HYPOTHESIS AND RATIO NALE  ................................ ................................ .......... 22 
3.1. Hypothesis  ................................ ................................ ................................ .................. 22 
3.2. Rationale  ................................ ................................ ................................ ..................... 22 
3.2.1.  Rationale for Study  ................................ ................................ ................................ .....22 
3.2.2.  Rationale for Study Design  ................................ ................................ ......................... 22 
3.2.3.  Rationale for Dose Selection  ................................ ................................ ...................... 23 
3.2.3.1.  Dose and Regimen of Dupilumab ................................ ................................ ............... 23 
3.2.3.2.  Dose and Regimen of SCIT  ................................ ................................ ........................ 23 
3.2.4.  Rationale for Dose of SCIT and Up -titration Regimen  ................................ .............. 24 
3.2.5.  Rationale for Choice of Allergen and Its Route of Administration  ............................ 24 
3.2.6.  Rationale for Nas al Allergen Challenge  ................................ ................................ .....25 
3.2.7.  Rationale for Primary Endpoint  ................................ ................................ .................. 25 
3.2.8.  Rationale for Other Endpoints  ................................ ................................ .................... 25 
3.2.8.1.  Ratio of Allergen -Specific IgG4 to IgE in Serum  ................................ ...................... 25 
3.2.8.2.  Nasal: Early -Phase (0 –60 min) and Late -Phase (6 hr) Reaction to Nasal 
Allergen Challenge  ................................ ................................ ................................ .....26 
3.2.8.3.  Skin: Early -Phase (0 –60 min) and Late -Phase (6 hr) Skin Reaction to 
Allergen Chal lenge  ................................ ................................ ................................ .....27 
3.2.8.4.  Serum TARC and Total IgE  ................................ ................................ ....................... 27 
3.2.8.5.  Basophil Sensitivity Test for Timothy Grass ................................ .............................. 27 
3.2.8.6.  Frequency of Circulating Th2A Cells  ................................ ................................ ......... 28 
3.2.8.7.  Type 2 Inflammation in the Nasal Mucosa in Response to a NAC as 
Measured by RNA Sequence and Ge ne Expression Analysis  ................................ ....28 
3.2.8.8.  Rationale for Study Duration  ................................ ................................ ...................... 29 
4. STUDY VARIABLES ................................ ................................ ................................ 29 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 6 of 87 
CONFIDENTIAL  4.1. Demographic and Baseline Characteristics  ................................ ................................ 29 
4.2. Primary and Secondary Endpoints ................................ ................................ .............. 29 
4.2.1.  Primary Endpoint  ................................ ................................ ................................ ........ 29 
4.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..30 
4.2.3.  Exploratory Endpoints  ................................ ................................ ................................ 30 
4.3. Pharmacokinetic Variables  ................................ ................................ ......................... 31 
4.4. Anti-Drug Antibody Variables  ................................ ................................ ................... 31 
5. STUDY DESIGN  ................................ ................................ ................................ .......31 
5.1. Study Description and Duration  ................................ ................................ ................. 31 
5.1.1.  Dosing and Administration  ................................ ................................ ......................... 32 
5.1.1.1.  Dupilumab or Dupilumab Placebo  ................................ ................................ ............. 32 
5.1.1.2.  SCIT and Placebo Matching SCIT  ................................ ................................ ............. 32 
5.2. Screening  ................................ ................................ ................................ .................... 33 
5.3. Randomize d Treatment Period (16 Weeks)  ................................ ................................ 35 
5.3.1.  Randomization  ................................ ................................ ................................ ............ 35 
5.3.2.  Study Design Safety Considerations for SCIT  ................................ ........................... 35 
5.4. Post-Treatment Follow -up Period (8 Weeks):  ................................ ............................ 36 
5.5. End of Study Definition  ................................ ................................ .............................. 36 
5.6. Planned Interim Analysis  ................................ ................................ ............................ 36 
6. SELECTION, WITHDRAWA L, AND REPLACEMENT O F SUBJECTS  .............. 36 
6.1. Number of Subjects Planned  ................................ ................................ ...................... 36 
6.2. Study Population  ................................ ................................ ................................ ......... 36 
6.2.1.  Inclusion Criteria  ................................ ................................ ................................ ........ 36 
6.2.2. Exclusion Criteria  ................................ ................................ ................................ .......37 
6.3. Premature Withdrawal from the Study  ................................ ................................ .......40 
6.4. Replacement of Subjects  ................................ ................................ ............................. 40 
7. STUDY TREATMENTS ................................ ................................ ............................ 40 
7.1. Investigational and Reference Treatments  ................................ ................................ ..40 
7.1.1.  Dupilumab Injection:  Investigational Treatment  ................................ ....................... 40 
7.1.2.  Timothy Grass SCIT:  Reference Treatment  ................................ .............................. 41 
7.1.3.  Timing of Dupilumab/placebo and SCIT/placebo  ................................ ...................... 43 
7.2. Rescue Treatments  ................................ ................................ ................................ ......44 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 7 of 87 
CONFIDENTIAL  7.3. Dose Modification and Study Treatment Discontinuation Rules  ............................... 44 
7.3.1.  Dose Modification  ................................ ................................ ................................ ......44 
7.3.2.  Study Drug Discontinuation (Dupilumab or Placebo for Dupilumab and 
SCIT or Placebo for SCIT)  ................................ ................................ ......................... 44 
7.3.3.  Reasons for Permanent Discontinuation of Study Drug (Dupilumab or 
Placebo for D upilumab and SCIT or Placebo for SCIT)  ................................ ............ 45 
7.3.3.1.  Reasons for Temporary Discontinuation of Study Drug (Dupilumab or 
Placebo for D upilumab and SCIT or Placebo for SCIT)  ................................ ............ 45 
7.4. Management of Acute Reactions  ................................ ................................ ................ 46 
7.4.1.  Acute Injection Reactions  ................................ ................................ ........................... 46 
7.4.1.1.  Systemic Injection Reactions  ................................ ................................ ...................... 46 
7.5. Method of Treatment Assignment  ................................ ................................ .............. 46 
7.5.1.  Blinding  ................................ ................................ ................................ ...................... 46 
7.5.2.  Emergency Unblinding  ................................ ................................ ............................... 47 
7.6. Treatment Logistics and Accountability  ................................ ................................ .....47 
7.6.1.  Packaging, Labeling, and Storage  ................................ ................................ .............. 47 
7.6.2.  Supply and Disposition of Treatments  ................................ ................................ .......47 
7.6.3.  Treatment Accountability  ................................ ................................ ........................... 48 
7.6.4.  Treatment Compliance  ................................ ................................ ................................ 48 
7.7. Concomitant Medications and Procedures  ................................ ................................ .48 
7.7.1.  Prohibited Medications (After Randomization) and Procedures  ................................ 48 
7.7.2.  Permitted Medications and Procedures  ................................ ................................ ......48 
8. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......49 
8.1. Schedule of Events  ................................ ................................ ................................ .....49 
8.1.1.  Footnotes for the Schedule of Events Table  ................................ ............................... 54 
8.1.2.  Early Termination Visit  ................................ ................................ .............................. 55 
8.1.3.  Unscheduled Visits  ................................ ................................ ................................ .....55 
8.2. Study Procedures  ................................ ................................ ................................ ........ 55 
8.2.1.  Efficacy Procedures  ................................ ................................ ................................ ....55 
8.2.1.1.  NAC and NAC assessments:  TNSS, TOSS, PNIF, and Total Sneezes  ..................... 55 
8.2.1.2.  Skin Prick Test with Serial Allergen Titration  ................................ ........................... 56 
8.2.1.3.  Intradermal Allergen Injection  ................................ ................................ ................... 56 
8.2.1.4.  Nasal Brushing  ................................ ................................ ................................ ............ 57 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 8 of 87 
CONFIDENTIAL  8.2.1.5.  Nasal Fluid Collection  ................................ ................................ ................................ 57 
8.2.2.  Safety Procedures  ................................ ................................ ................................ .......57 
8.2.2.1.  Vital Signs  ................................ ................................ ................................ .................. 57 
8.2.2.2.  Physical Examination  ................................ ................................ ................................ .57 
8.2.2.3.  Electrocardiogram  ................................ ................................ ................................ .......58 
8.2.2.4.  Spirometry  ................................ ................................ ................................ .................. 58 
8.2.2.5.  Peak Expiratory Flow  ................................ ................................ ................................ .58 
8.2.2.6.  Laboratory Testing  ................................ ................................ ................................ ......58 
8.2.3.  Drug Concentration and Measurements  ................................ ................................ .....59 
8.2.4.  Anti-Drug Antibody Measurements and Samples  ................................ ...................... 59 
8.2.5.  Pharmacodynamic and Biomarker Procedures  ................................ ........................... 60 
8.2.5.1.  Biomarker Sample collections  ................................ ................................ .................... 60 
  
  
9. SAFETY DEFINITIONS, REPORTING, AND MONIT ORING  ............................. 61 
9.1. Obligations of Investigator  ................................ ................................ ......................... 61 
9.2. Obligations of Sponsor  ................................ ................................ ............................... 61 
9.3. Definitions  ................................ ................................ ................................ .................. 62 
9.3.1.  Adverse  Event  ................................ ................................ ................................ ............. 62 
9.3.2.  Serious Adverse Event  ................................ ................................ ................................ 62 
9.4. Recording and Reporting Adverse Events  ................................ ................................ ..62 
9.4.1.  Adverse Events  ................................ ................................ ................................ ........... 62 
9.4.2.  Serious Adverse Events  ................................ ................................ .............................. 63 
9.4.3.  Other Events that Require Accelerated Reporting to Sponsor  ................................ ...63 
9.4.4.  Reporting Adverse Events Leading to Withdrawal from the Study  ........................... 64 
9.4.5.  Abnormal Laboratory, Vital Signs, or Electrocardiogram Results  ............................. 64 
9.4.6.  Follow -up ................................ ................................ ................................ .................... 64 
9.5. Evaluation of Severity and Causality  ................................ ................................ ......... 65 
9.5.1.  Evaluation of Severity  ................................ ................................ ................................ 65 
9.5.2.  Evaluation of Causality  ................................ ................................ ............................... 65 
9.6. Safety Monitoring  ................................ ................................ ................................ .......69 
9.7. Investigator Alert Notification  ................................ ................................ .................... 69 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 9 of 87 
CONFIDENTIAL  10. STATISTICAL PLAN ................................ ................................ ................................ 69 
10.1.  Statistical Hypothesis  ................................ ................................ ................................ ..69 
10.2.  Justification of Sample Size ................................ ................................ ........................ 70 
10.3.  Analysis Sets  ................................ ................................ ................................ ............... 70 
10.3.1.  Efficacy Analysis Sets  ................................ ................................ ................................ 70 
10.3.2.  Safety Analysis Set  ................................ ................................ ................................ .....70 
10.3.3.  Pharmacokinetic Analysis Sets  ................................ ................................ ................... 70 
10.3.4.  Anti-Drug Antibody Analysis Sets  ................................ ................................ ............. 70 
10.4.  Statistical Methods  ................................ ................................ ................................ ......71 
10.4.1.  Subject Disposition  ................................ ................................ ................................ .....71 
10.4.2.  Demography and Baseline Characteristics  ................................ ................................ .71 
10.4.3.  Efficacy Analyses  ................................ ................................ ................................ .......71 
10.4.3.1.  Primary Efficacy Analysis  ................................ ................................ .......................... 71 
10.4.3.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 72 
10.4.3.3.  Multiplicity Considerations  ................................ ................................ ........................ 72 
10.4.3.4.  First-Step Analysis ................................ ................................ ................................ ......72 
10.4.4.  Safety Analysis  ................................ ................................ ................................ ........... 72 
10.4.4.1.  Adverse Events  ................................ ................................ ................................ ........... 72 
10.4.4.2.  Other Safety  ................................ ................................ ................................ ................ 73 
10.4.4 .3. Treatment Exposure  ................................ ................................ ................................ ....73 
10.4.4.4.  Treatment Compliance  ................................ ................................ ................................ 74 
10.4.5.  Pharmacokinetics  ................................ ................................ ................................ ........ 74 
10.4.6.  Analysis of Anti -Drug Antibody Data  ................................ ................................ ........ 74 
10.4.7.  Analysis of Pharmacodynamic and Exploratory Biomarker Data  .............................. 74 
10.5.  Additional Statistical Data Handling Conventions  ................................ ..................... 74 
10.6.  Statistical Considerations Surrounding the Premature Termination of a Study  ......... 75 
11. DATA MANAGEMENT AND ELECTRONIC SYSTEMS  ................................ .....75 
11.1.  Data Management  ................................ ................................ ................................ .......75 
11.2.  Electronic Systems  ................................ ................................ ................................ ......75 
12. STUDY MONITORING  ................................ ................................ ............................ 76 
12.1.  Monitoring of Study Sites  ................................ ................................ ........................... 76 
12.2.  Source Document Requirements  ................................ ................................ ................ 76 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 10 of 87 
CONFIDENTIAL  12.3.  Case Report Form Requirements  ................................ ................................ ................ 76 
13. AUDITS AND INSPECTIO NS ................................ ................................ ................. 76 
14. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ .......... 77 
14.1.  Good Clinical Practice Statement  ................................ ................................ ............... 77 
14.2.  Subjects Confidentiality and Data Protection  ................................ ............................. 78 
14.3.  Institutional Review Board/Ethics Comm ittee ................................ ........................... 78 
15. PROTOCOL AMENDMENTS  ................................ ................................ .................. 78 
16. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE -OUT OF A 
SITE  ................................ ................................ ................................ ............................ 78 
16.1.  Premature Termination of the Study  ................................ ................................ ........... 78 
16.2.  Close -out of a Site  ................................ ................................ ................................ ......79 
17. STUDY DOCUMENTATION  ................................ ................................ ................... 79 
17.1.  Certification of Accuracy of Data  ................................ ................................ ............... 79 
17.2.  Retention of Records  ................................ ................................ ................................ ..79 
18. DATA QUALITY ASSURAN CE ................................ ................................ .............. 80 
19. CONFIDENTIALITY  ................................ ................................ ................................ 80 
20. FINA NCING AND INSURANCE  ................................ ................................ ............. 80 
21. PUBLICATION POLICY  ................................ ................................ .......................... 80 
22. REFERENCES  ................................ ................................ ................................ ........... 81 
23. INVESTIGATOR’S AGREE MENT  ................................ ................................ .......... 85 
SIGNATURE OF SPONSOR ’S RESPONSIBLE OFFIC ERS ................................ ..................... 87 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 11 of 87 
CONFIDENTIAL  LIST OF TABLES  
Table  1: SCIT Up -Titration and Maintenance Regimen ................................ ........................... 42 
Table  2: Dosin g Schedule for Dupilumab/Placebo with Respect to SCIT/Placebo  ................. 43 
Table  3: Schedule of Events  ................................ ................................ ................................ .....50 
 
LIST OF FIGURES  
Figure  1: Study Flow Diagram  ................................ ................................ ................................ ...33 
 
LIST OF APPENDICES  
Appendix  1. TOXICITY GRADING SCALE FOR GRADING ALLERGIC 
REACTIONS AND ANAPHYLAXIS – COMMON TER MINOLOGY 
CRITERIA FOR ADVERSE EVENTS (CTCAE VERSION 4.0, 
PUBLISHED 28 MAY 2009; V4.03, 14 JUNE 2010)  ................................ ............... 86 
 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 12 of 87 
CONFIDENTIAL  CLINICAL STUDY PROTO COL SYNOPSIS  
Title  A Study To Evaluate The Efficacy Of Dupilumab As An 
Adjunct For Subcutaneous Grass Immunotherapy To Reduce 
Provoked Allergic Rhinitis Symptoms Usin g The Nasal 
Allergen Challenge Model  
Site Location(s)  North America  
Objective(s)  The primary objective is to assess whether 16 weeks of 
treatment with dupilumab as an adjunct to Timothy Grass 
subcutaneous immunotherapy (SCIT) improves upon the 
efficacy of Timothy Grass SCIT to reduce provoked allergic 
rhinitis symptoms, as measured by Total Nasal Symptom Score 
(TNSS) after nasal allergen challenge (NAC) with Timothy 
Grass extract at week 17.  
The secondary objectives of the study are:  
 To assess whether 16  weeks of treatment with dupilumab 
as compared to placebo reduces provoked allergic rhinitis 
symptoms, as measured by TNSS after nasal allergen 
challenge (NAC) with Timothy Grass extract  
 To assess whether 16 weeks of treatment with dupilumab 
as compared t o dupilumab + SCIT reduces provoked 
allergic rhinitis symptoms, as measured by TNSS after 
nasal allergen challenge (NAC) with Timothy Grass 
extract  
 To assess changes in serum Timothy Grass -specific IgG4, 
serum Timothy Grass -specific IgE, and ratio of serum 
Timothy Grass -specific IgG4 to IgE over 16 weeks of 
treatment with dupilumab + SCIT as compared to SCIT 
monotherapy  
 To evaluate the safety and tolerability of 16 weeks of 
treatment with dupilumab as an adjunct to Timothy Grass 
SCIT  
Study Design  This is a phase 2a, multicenter, randomized, double -blind, 
parallel group, 4 -arm study of dupilumab as an adjunct to grass 
SCIT in adult subjects with a history of allergic rhinitis.  The 
entire study will be conducted outside of Timothy Grass allergy 
season.  The 4 arms are:  
1. Timothy Grass SCIT up -titrated to a 4,000 Bioequivalent 
allergy unit (BAU) maintenance dose + dupilumab 
subcutaneous (SC) [300 mg every 2 weeks (Q2W), after 
600 mg loading dose]  
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 13 of 87 
CONFIDENTIAL  2. Timothy Grass SCIT up -titrated to a 4,000 BAU mai ntenance 
dose + placebo for dupilumab  
3. Placebo for SCIT plus dupilumab (SC 300 mg Q2W, after 
600 mg loading dose)   
4. Placebo for SCIT plus placebo for dupilumab  
Study Duration  The duration of the study is approximately 24 weeks excluding 
the screening  period, including 16 weeks on study drugs and 
8 weeks follow -up  
End of Study Definition  The end of study is defined as the last visit of the last subject.  
Population  Adult subjects with a history of allergic rhinitis   
 Sample Size:  Approximately 100 subjects, 25 per treatment group  
 Target Population:  Male and female subjects aged 18 to 55 with a history of 
Timothy Grass pollen –induced seasonal allergic rhinitis  
Treatment(s)   
 Study Drug  
 Dose/Route/Schedule:  Dupilumab  
300 mg SC Q2W after loading dose of 600 mg SC on day 1  
 Reference Drug  
 Dose/Route/Schedule:  Timothy Grass Extract SCIT   
Cluster SCIT up -titration regimen of Timothy Grass extract 
over 8 weeks followed by maintenance SC injections for the 
following 8 weeks (regimen described in Table  1) 
 Placebo  
 Route/Schedule:  Placebo for dupilumab  
SC Q2W with loading dose after placebo loading dose SC on 
Day 1  
 Placebo  
 Route/Schedule:  Placebo for SCIT  
Cluster SCIT up -titration regimen of placebo over 8 weeks 
followed by maintenance SC injections for the following 
8 weeks  
Endpoint(s)   
Primary:  The primary endpoint is the percent change in the area under 
the curve (AUC) for TNSS (0 -1 hr post peak TNSS) in response 
to a NAC at week 17 from the pretreatment baseline TNSS 
AUC (0 -1 hr post peak TNSS) for dupilumab + SCIT as 
compared to placebo +SCIT monotherapy.  
Secondary   Change from baseline in TNSS AUC post NAC over the 
first hour after t he challenge (0 -1 hr post peak TNSS) at 
week 17 for dupilumab + SCIT as compared to SCIT 
monotherapy  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 14 of 87 
CONFIDENTIAL   Change and percent change from baseline in TNSS area 
under curve (AUC) post NAC over the first hour of the 
challenge (0 -1 hr post peak TNSS) at week 17 for  
dupilumab monotherapy as compared to placebo  
 Change and percent change from baseline in the TNSS 
AUC post NAC over the first hour of the challenge (0 -
1 hr post peak TNSS) at week 17 for dupilumab + SCIT 
as compared to dupilumab + placebo for SCIT.  
 Change and percent change from baseline (last 
pretreatment measurement) to week  17 in serum 
Timothy Grass sIgG4 for dupilumab + SCIT as 
compared to SCIT monotherapy  
 Change and percent change from baseline (last 
pretreatment measurement) to week  17 in serum  
Timothy Grass sIgE  for dupilumab + SCIT as compared 
to SCIT monotherapy  
 Change from baseline (last pretreatment measurement) 
to week  17 in log transformed value of serum Timothy 
Grass sIgG4 to Timothy Grass sIgE ratio for dupilumab 
+ SCIT as compared to S CIT monotherapy  
 Incidence rates of treatment emergent adverse events 
(TEAEs) and serious TEAEs through end of study  
Procedures and Assessments  Efficacy will be assessed during the study at specified study site 
visits by the investigator(s) and include measurements of TNSS 
after NAC, TOSS after NAC, PNIF after NAC, intradermal 
skin challenge testing, and SPT with serial allergen titration.  
Safety  will be assessed by vital signs, physical examination, 
clinical laboratory tests, ECGs, and clinical evaluations.  All 
AEs that occur from the time of the informed consent until the 
end of the study will be monitored by the investigator.   
Statistical Pl an Sample Size Consideration:  
It is estimated that with 25 subjects per group, at the 2 -sided 
5% significance level, the study will have 80% power to detect 
a difference of 29% between dupilumab plus SCIT and placebo 
plus SCIT monotherapy with respect to percent change from 
baseline in TNSS AUC (0 -1 hr) at week 17, assuming that the 
mean percent changes from baseline values are -55% and -26% 
and a common standard deviation of 35% for dupilumab plus 
SCIT and placebo plus SCIT monotherapy, respectively.  
 
 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 15 of 87 
CONFIDENTIAL  Efficacy Analysis Sets:  
The full analysis set includes all randomized subjects. Efficacy 
analyses will be based on the treatment allocated at 
randomization (as randomized).  
The per protocol set includes all subjects in the FAS except for 
those who are exc luded because of major protocol violations.  
A major protocol violation is one that may affect the 
interpretation of study results.  
Analysis Methods:  
Primary Efficacy Analyses  
The primary endpoint will be analyzed by using the multiple 
imputation with anal ysis of covariance (ANCOVA) model.  
Missing data will be imputed 40 times to generate 40 complete 
data sets by using the Statistical Analysis System (SAS) 
procedure MI.  Each of the 40 complete datasets will be 
analyzed using an ANCOVA model with treatment  and relevant 
baseline as covariates.  The SAS MIANALYZE procedure will 
then be used to generate valid statistical inferences by 
combining results from the 40 analyses using Rubin’s formula.  
All observed data will be used for analysis.  Sensitivity analysi s 
such as ANCOVA model with last observation carry forward 
(LOCF) method will also be conducted.  Additional details on 
sensitivity analyses will be provided in the statistical analysis 
plan.  
Secondary Efficacy Analyses  
The continuous secondary efficacy en dpoints will be analyzed 
using the same approach as that used for the analysis of the 
primary endpoint.  
The biomarker related continuous endpoint will be analyzed 
using a rank based ANCOVA model with treatment and 
relevant baseline as covariates.  The LOCF  method will be used 
to impute the missing data.  
Safety Analyses  
Safety analysis will be based on the safety analysis set. This 
includes reported TEAEs and other safety information (eg, 
clinical laboratory evaluations, vital signs, and 12 -lead ECG 
results) . 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 16 of 87 
CONFIDENTIAL  LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AD Atopic dermatitis  
ADA  Anti-drug antibody  
AE Adverse event  
AESI  Adverse event of special interest  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
AST  Aspartate aminotransferase  
AUC  Area  under curve  
BAU  Bioequivalent allergy unit  
BUN  Blood urea nitrogen  
CPK  Creatine phosphokinase  
CRF  Case report form (electronic or paper)  
CRO  Contract research organization  
CTCAE  Common Terminology Criteria for Adverse Events  
EC Ethics Committee  
EC50  50% of maximal activation  
ECG  Electrocardiogram  
ECP Eosinophil cationic protein  
EDC  Electronic data capture  
EPR Early phase reaction  
FAS Full analysis set  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HDL  High -density lipoprotein  
HIV Human Immunodeficiency Virus  
ICF Informed consent form  
ICH International Council for Harmonisation  
IFN-γ Interferon Gamma  
IgE Immunoglobulin E  
IgG4  Immunoglobulin G4  
IL-4 Interleukin 4  
IL-4Rα Interleukin 4 receptor alpha  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 17 of 87 
CONFIDENTIAL  IL-5 Interleukin 5  
IL-13 Interleukin 13  
ISR Injection site reactions   
IRB Institutional Review Board  
LABA  Long -acting beta agonist  
LAMA  Long -acting muscarinic antagonist  
LDH  Lactate dehydrogenase  
LDL  Low-density lipoprotein  
LPR Late phase reaction  
MedDRA  Medical Dictionary for Regulatory Activities  
NAC  Nasal allergen challenge  
MI Multiple imputation  
NIMP  Non-investigational Medical Product  
NCI-CTCAE  National Cancer Institute -Common Terminology Criteria for Adverse Events  
NP Nasal polyposis  
PBMC  Peripheral Blood Mononuclear Cells  
PBO  Placebo  
PCSV  Potentially clinically significant value  
PK Pharmacokinetic  
PNIF  Peak nasal inspiratory flow  
POM  Proof of mechanism  
PT Preferred term  
RBC  Red blood cell  
Regeneron  Regeneron Pharmaceuticals, Inc.  
RNA  Ribonucleic acid  
sIgE Specific immunoglobulin E  
sIgG4  Specific immunoglobulin G4  
SAE  Serious adverse event  
SAF Safety analysis set  
SAP Statistical analysis plan  
SAS Statistical Analysis System  
SC Subcutaneous  
SCIT  Subcutaneous immunotherapy  
SD Standard deviation  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 18 of 87 
CONFIDENTIAL  SLIT  Sublingual immunotherapy  
SOC  System organ class  
SPT Skin prick test  
SQ Standardized Quality  
SUSAR  Suspected unexpected serious adverse reaction  
TARC  Thymus and activation -regulated chemokine  
TEAE  Treatment -emergent adverse event  
Th2 Type 2 t -cells 
Th2A  Th2A are a unique Th2 subcell in allergic individuals  
TNSS  Total nasal symptom score  
TOSS  Total ocular symptom score  
WBC  White blood cell  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 19 of 87 
CONFIDENTIAL  1. INTRODUCTION  
Subcutaneous immunotherapy (SCIT) is a disease modifying treatment option for patients with 
allergic rhinitis triggered by aeroallergens (such as pollen, animal dander, or dust).  SCIT is 
recommended when pharmacological therapies are not sufficient to control symptoms.  During 
SCIT, increasing doses of the inciting aller gen are administered, followed by a maintenance dose 
for several years, with the goal of inducing immunological changes leading to symptom 
amelioration while on therapy, as well as sustained desensitization off SCIT (immune tolerance). 
The pathobiology of allergic disease is complex, involving many cell types and genetic 
susceptibility.  Data suggest that SCIT results in memory T and B cell responses, 
allergen -specific immunoglobulin shifts from immunoglobulin E (IgE) to immunoglobulin G4 
(IgG4), decreased Type 2 cytokines in tissues, decreased tissue migration of eosinophils and 
decreased mediator release from tissue mast cells, basophils and eosinophils ( Akdis, 2011 ) 
(Larche, 2006 ).  The increase  in allergen -specific IgG4 (sIgG4) titers observed in SCIT may 
inhibit effector cell activation by binding to allergen, thereby blocking binding to high affinity 
IgE pre -loaded on Fc (epsilon) receptors expressed on mast cells and basophils ( Flicker,  2003 ).  
Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin -4 (IL -4) and 
interleukin -13 (IL -13) signaling by specifically binding to the IL -4Rα subunit shared by the IL -4 
and IL -13 receptor complexes.  Blockin g IL -4Rα with dupilumab inhibits IL -4 and IL -13 
cytokine -induced responses, including the release of proinflammatory cytokines, chemokines 
and IgE.  IL -4 and IL -13 play key roles in the pathophysiology of allergic diseases, as 
demonstrated by dupilumab’s e fficacy shown in clinical studies in atopic diseases such as atopic 
dermatitis (AD), asthma, nasal polyposis (NP) and eosinophilic esophagitis.  This is the basis for 
the rationale to evaluate whether dupilumab may enhance allergy immunotherapy.  Dupilumab  
has clinically demonstrated down -modulation of the Type 2 pathway and has the potential to 
complement the immunoregulatory mechanisms of allergen immunotherapy.  IL -4 and IL -13 are 
important cytokines that trigger class switching in B -cells (Lundgren M, 1989 ) and dupilumab 
has been shown to suppress serum total and specific immunoglobulin E (sIgE) over time in all 
studies where measured; serum total IgE decreased by ~30% after 12 weeks of weekly 300 mg 
treatment in AD; for sIgE, studies in AD and asthma patients show a ~40% reduction at week 16 
and ~50% reduction at week 24 (Regeneron unpublished data).  In a post -hoc analysis of a 
dupilumab dose -ranging study in moderate -to-severe asthma patients with comorbid allergic 
rhinitis, patients had a significant reduction in reported rhinitis symptoms with dupilumab 
compared to placebo.  Because of these data and the role of IL -4 and IL -13 in immunoglobulin 
class switching, we anticipate that dupilumab as an adjunct to SCIT, will e nhance the change of 
allergen specific IgG4/IgE ratio in SCIT + dupilumab treated subjects as compared to subjects 
treated with SCIT alone.  In patients with AD, dupilumab modulated several Type 2 chemokines, 
including CCL17 (thymus and activation -regulate d chemokine [TARC]) in serum and skin 
tissue, therefore we anticipate that dupilumab will modulate Type 2 chemokines and cytokines in 
subjects with a history of allergic rhinitis, which may improve tolerability of SCIT up -dosing 
(Beck, 2014 ) (Hamilton, 2014 ).  A reduction in the production of Type 2 cytokines and 
chemokines by dupilumab is also likely to potentiate the reduction of provoked allergic rhinitis 
symptoms by SCIT.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 20 of 87 
CONFIDENTIAL  There is an unmet n eed for a more efficacious treatment of allergic disease.  SCIT can provide 
long-lasting protection from allergic disease, but it also carries a risk of adverse reactions, has 
variable efficacy between patients, and can take at least 3 years to induce immu ne tolerance 
(Durham,  1999 ) (Durham, 2012 ) (Leung, 2010 ) (Durham, 2016 ).  At the start of SCIT, patients 
receive injections of increasing doses of the allergen at weekly intervals over several weeks to 
months, under tightly monitored medical supervision.  The gradual dose escalation enables 
tolerability to therapy and mitigates risk of severe hypersensitivity reactions related to allergen 
administration.  Side effects occur in 40 -50 % of patients ranging from mild reactions 
(eg, swelling, injection site reaction, de novo allergic response, and urticaria) to life -threatening 
reactions (eg, asthma exacerbation and anaphylaxis) ( Frew, 2006a ).  Asthma is a major risk 
factor for life -threatening systemic reactions to SCIT and therefore moderate -severe asthma is a 
contraindication to SCIT.  Therefore with proper patient selection, risk of severe reactions can  be 
mitigated ( Frew, 2010 ) (Frew, 2006a ).  Induction of Type 2 pathway cytokines upon SCIT 
initiation can transiently exacerbate allergic symptoms, resulting in SCIT dose limitations during 
up-titration in some patients.  Blockade of these cytokines by dupilumab may improve 
tolerability of the desensitization process, in addition to improving overall safety and efficacy by 
further suppression of IgE production.   
Therefore, dupilumab may: 1) limit s ymptoms of the desensitization process so that maximal 
SCIT uptitration may be achieved 2) improve the efficacy of the sensitization process via its 
suppressive effect on IgE production, and 3) reduce allergic symptoms directly by other 
mechanisms includin g the inhibition of allergen specific Type 2 t -cells (Th2) cell number and 
function with downstream effects on mast cells, eosinophils, and basophils.  
This trial is a 4 -arm, placebo -controlled, double -blind, randomized, parallel -group, 
proof -of-concept st udy over a 16  week treatment period followed by an 8 week safety follow -up 
period in approximately 100 subjects with a history of Timothy Grass -induced allergic rhinitis.  
Allergy to Timothy and rye grasses are the most prevalent seasonal allergies and gra ss 
immunotherapy is the most studied form of allergen immunotherapy ( Salo, 2014 ).  The primary 
objective will be to assess whether dupilumab in combination with SCIT can reduce provoked 
allergic symptoms more than SCIT alone by  Total Nasal Symptom Score (TNSS) after nasal 
allergen challenge (NAC) with Timothy Grass allergen.  The entire 17 week study will be 
conducted outside of grass allergy season so that environmental allergens do not interfere with 
the provoked allergy sympt oms by the NAC.  TNSS is a patient -reported composite symptom 
assessment of congestion, itching, rhinorrhea and sneezing. Cluster SCIT dosing (multiple 
injections per week) accelerates the onset of efficacy of SCIT.  Therefore, up -titration of SCIT 
over 8 weeks (rather than conventional regimen of 12 weeks) plus 8 weeks of maintenance SCIT 
will be investigated in this study with the goal to show early induction of treatment response.  
We hypothesize that efficacy of SCIT, as measured by an improvement in TN SS in response to 
NAC, will be significantly augmented by dupilumab.  The secondary objectives will assess 
safety and tolerability of dupilumab as an adjunct to SCIT, whether dupilumab monotherapy 
reduces provoked allergic rhinitis symptoms more than place bo, and whether dupilumab in 
combination with SCIT changes Timothy Grass -specific IgG4, Timothy -Grass specific IgE, and 
the ratio of Timothy -grass specific IgG4/IgE more than SCIT alone.  Exploratory objectives will 
assess early -phase (0 –1 hr) and late -phase (1 -6 h) nasal and skin responses following nasal and 
intradermal allergen administration, Total Ocular Symptom Score (TOSS) after NAC, serum 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 21 of 87 
CONFIDENTIAL  TARC, and total IgE.  Additional biomarkers, to be included in a separate Exploratory 
Biomarker Report, will inc lude basophil sensitivities to grass allergen, allergen -specific Th2A 
cells, and changes in type 2 inflammation in the nasal mucosa after NAC as measured by RNA 
sequencing and nasal fluid cytokine concentration.  
2. STUDY OBJECTIVES  
2.1. Primary Objective  
 To assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy 
Grass SCIT improves upon the efficacy of Timothy Grass SCIT to reduce provoked 
allergic rhinitis symptoms, as measured by TNSS after NAC with Timothy Grass 
extract at week 17  
2.2. Seco ndary Objectives  
 To assess whether 16 weeks of treatment with dupilumab as compared to placebo 
reduces provoked allergic rhinitis symptoms, as measured by TNSS after NAC with 
Timothy Grass extract  
 To assess whether 16 weeks of treatment with dupilumab as compared to dupilumab 
+ SCIT reduces provoked allergic rhinitis symptoms, as measured by TNSS after 
nasal allergen challenge (NAC) with Timothy Grass extract  
 To assess changes in serum Timothy -grass -specific IgG4, serum Timothy 
Grass -specific IgE, and rat io of serum Timothy Grass -specific IgG4 to IgE over 
16 weeks of treatment with dupilumab + SCIT as compared to SCIT monotherapy  
 To evaluate the safety and tolerability of 16 weeks of treatment with dupilumab as an 
adjunct to Timothy Grass SCIT  
2.3. Other Objec tives  
 To assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy 
Grass SCIT improves upon the efficacy of Timothy Grass SCIT to reduce provoked 
allergic conjunctivitis symptoms, as measured by TOSS after NAC with Timothy 
Grass extract.   
 To assess whether 16 weeks of treatment with dupilumab as compared to placebo 
reduces provoked allergic conjunctivitis symptoms, as measured by TOSS after NAC 
with Timothy Grass extract.  
 To assess the changes in both early -phase (0 –1 hr) and late -phase (1-6 hr) skin 
responses following Skin Prick Test with Serial Allergen Titration  and intradermal 
administration of Timothy Grass, respectively, over 16 weeks of treatment with 
dupilumab monotherapy (+ placebo for SCIT), SCIT monotherapy (+  placebo for 
dupilumab), dupilumab + SCIT, and placebo for SCIT + placebo for dupilumab  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 22 of 87 
CONFIDENTIAL   To assess changes in peak nasal inspiratory flow (PNIF) after NAC over 16 weeks of 
treatment with dupilumab monotherapy (+ placebo for SCIT), SCIT monotherapy 
(+ placebo for dupilumab),  dupilumab + SCIT, and placebo for SCIT + placebo for 
dupilumab  
 To assess total sneeze count after NAC over 16 weeks of treatment with dupilumab 
monotherapy (+ placebo for SCIT), SCIT monotherapy (+ placebo for dupilumab), 
dupilumab + SCIT, and placebo for  SCIT + placebo for dupilumab  
 To assess changes in serum TARC over 16 weeks of treatment with dupilumab 
monotherapy (+ placebo for SCIT), SCIT monotherapy (+ placebo for dupilumab), 
dupilumab + SCIT, and placebo for SCIT + placebo for dupilumab  
 To assess c hanges in serum total IgE over 16 weeks of treatment with dupilumab 
monotherapy (+ placebo for SCIT), SCIT monotherapy (+ placebo for dupilumab), 
dupilumab + SCIT, and placebo for SCIT + placebo for dupilumab  
3. HYPOTHESIS AND RATIO NALE  
3.1. Hypothesis  
Dupilumab in combination with SCIT will reduce provoked allergic rhinitis symptoms, as 
measured by TNSS after NAC, two -fold as compared to SCIT alone.  
3.2. Rationale  
3.2.1.  Rationale for Study  
This study is a double blind, placebo -controlled, parallel design study i n grass allergic subjects.  
Four treatment groups are required to provide informative controls and minimize bias on clinical 
endpoints: dupilumab + SCIT, placebo for dupilumab + SCIT, dupilumab + placebo for SCIT 
and placebo for dupilumab + placebo for SCI T.  In addition, this study will allow the evaluation 
of dupilumab monotherapy on clinical rhinitis symptoms and related biomarkers.  
3.2.2.  Rationale for Study Design  
Dupilumab, with and without SCIT, will be tested in a 4 -arm, double -blind, randomized, 
parallel -group, proof -of-concept study of 16 week treatment period in approximately 
100 subjects with a history of Timothy Grass -induced allergic rhinitis using change from 
baseline in TNSS area under curve (AUC) post NAC over the first hour after the challenge (0 -1 
hr post peak TNSS) as the primary endpoint.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 23 of 87 
CONFIDENTIAL  3.2.3.  Rationale for Dose Selection  
3.2.3.1.  Dose and Regimen of Dupilumab  
Dupilumab at 300 mg every 2 weeks (Q2W) with a loading dose of 600 mg on day 1 will be used 
in this study, as this regimen is Food and Drug Administra tion (FDA) approved for AD and is 
effective in asthma.  Based on the pharmacokinetic profile of dupilumab, this dose regimen is 
expected to saturate binding to IL -4Ra, providing maximum inhibition of signaling and hence 
suppression of type 2 inflammation a nd Ig class switching to IgE.  Moreover, this dose of 
dupilumab significantly reduces sIgE by 12 weeks (Regeneron unpublished data), which should 
improve upon the sIgG4/IgE ratio elicited by SCIT by 17 weeks to therefore improve upon the 
efficacy of SCIT a s measured by TNSS in response to NAC after 17 weeks.  Subjects may 
administer the dupilumab at home after receiving the loading dose at the study site (and training 
to self -administer at home), but they will be given the opportunity to receive dupilumab a t the 
study site as well.  The loading dose will allow subjects to achieve efficacious concentrations 
quickly for this short study.  Dupilumab will be started one day prior to initiation of the SCIT 
regimen, and for subsequent doses dupilumab will be admin istered Q2W and will always be 
given on a different day than SCIT to assist with interpretation of adverse effects due to each 
agent.  Dupilumab will be dosed as follows: subjects will be given a loading dose of 600 mg 
dupilumab subcutaneous (SC) or placeb o on day 1, followed 2 weeks later by 300  mg Q2W SC, 
and to continue 300  mg Q2W SC for a total of 16 weeks.  In previous studies in patients like 
those expected to be enrolled in this study dupilumab has a safety profile similar to placebo 
except for an in creased incidence of injection site reactions.  Other common adverse events 
(AEs) were headache, nasopharyngitis, and upper respiratory tract infection and these were most 
commonly mild to moderate in severity.  In patients with AD, conjunctivitis and Herp es simplex 
were also reported at an increased incidence in patients receiving dupilumab compared to 
placebo ( Beck 2014 ) (Wenzel, 2016 ) (Bachert 2016 ). 
3.2.3.2.  Dose and Regi men of SCIT  
On the day following dupilumab dosing (up to 7 days after dupilumab loading dose), subjects 
will begin an up -titration regimen of Timothy Grass SCIT beginning at 1 bioequivalent allergy 
unit (BAU) up to 4,000 BAU, in a modified cluster regimen over 8 weeks, and then maintained 
on 4,000 BAU for the remaining 8 weeks  (Table  1).  This dosing regimen has previously been 
shown to give significant clinical efficacy and consistent kinetics of the sIgG4 and sIgE response 
(Frew, 2006b ), (Shamji, 2012 ).  Using a modified cluster regimen over 8 weeks to reach a 
4,000  BAU maintenance dose, the m ost common AEs were fatigue, urticaria, wheezing, chest 
tightness and flushing ( Ewbank, 2003 ).  As referenced previously, safety of modified cluster 
uptitration of SCIT versus conventional up -titration appears to have similar  local and systemic 
AE profile ( Creticos, 1992 ).  Additionally, as recommended by the American Academy of 
Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology 
to reduce local and systemic AEs during cluster SCIT, subjects will be pre -medicated with an 
oral H1 antihistamine prior to cluster SCIT dosing on all dosing days ( Cox, 2011 ).  However, 
oral H1 antihistamines are never to be administered within 5 days prior  to a study visit for NAC 
as antihistamines will interfere with the NAC.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 24 of 87 
CONFIDENTIAL  3.2.4.  Rationale for Dose of SCIT and Up -titration Regimen  
Per clinical guidelines, immunotherapy is typically initiated 12 -16 weeks before the allergen 
season to treat seasonal allergic rhi nitis.  Immunotherapy is often continued for a duration of 3 -5 
years to reach greater efficacy and achieve allergen immunotolerance.  In clinical studies, 
efficacy is typically assessed after 8 -12 months of treatment ( Bacher t, 2016 ) (Scadding, 2017 ) to 
investigate the maximal efficacy of SCIT on reduction of clinical symptoms during natural 
pollen exposure ( Bachert, 2016 ) or by NAC after ≥ 8 -12 months ( Scadding, 2017 ).  SCIT 
reduces symptoms by 25 -30% relative to placebo in these studies.  
Few studies have evaluated efficacy at time points earlier than 8 months.  However, the onset of 
symptom relief and increase in sIgG4 levels wi th SCIT occurs after reaching maintenance dose 
(ie, at the end of the up -titration phase [ Ewbank, 2003 ]).  With conventional SCIT up -titration 
regimens, this can take 8 -12 weeks of weekly dosing.  Cluster dosing, multiple inj ections per 
week, is an alternative to accelerate the onset of efficacy.  In a house dust mite SCIT study, 
6 week cluster dosing showed a marginal, but observable advantage to a 12 week conventional 
up-titration on clinical measures and a 50% more rapid ri se in sIgG4.  Adverse events rates were 
slightly lower with the cluster regimen than the conventional up -titrations, 3% and 4%, 
respectively ( Tabar,  2005 ).  A meta -analysis of 567 participants in 8 trials showed that cluster 
SCIT has similar effect in the reduction of both rhinitis symptoms and the requirement for 
anti-allergic medication compared with conventional SCIT.  The safety of cluster SCIT showed 
that no differences existed in the incidence of either local or systemic adverse reaction between 
the cluster group and control group ( Feng, 2014 ).  The current study proposes to evaluate the 
highest recommended dose of SCIT (4,000 BAU) provided in a modified cluster regimen so that 
an observable ch ange in treatment groups can be assessed in 17 weeks.  Efficacy will be assessed 
by changes in rhinitis symptoms after NAC (Section 4.2). 
3.2.5.  Rationale for Choice of A llergen and Its Route of Administration  
Grass SCIT immunotherapy was selected as an experimental model to test the effect of 
dupilumab on SCIT due to the availability of precedent clinical and biomarker data.  Few 
well-controlled studies have been conducte d with other allergens ( Canonica, 2013 ).  Besides 
grass specific immunotherapy sublingual immunotherapy (SLIT) and SCIT, there are limited 
studies of other allergen immunotherapies demonstrating efficacy in a NAC study.  The 
advantage of studying seasonal allergens, (ie, grass pollen), compared to perennial allergens (ie, 
cat, house dust mite), is that pollens induce broader symptomatology, induce sneezing, itchiness 
and nasal congestion, whereas the predominant symptom as sociated with perennial allergens is 
nasal congestion.  Hence, a study of grass pollen will inform about the efficacy of dupilumab as 
an adjuvant to SCIT treatment on broad rhinitis symptoms.  One limitation of using a seasonal 
allergy is that timing of st udy and seasonality are key considerations; this study must be 
conducted outside of pollen season to minimize the impact of environmental allergen exposure 
on study results.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 25 of 87 
CONFIDENTIAL  3.2.6.  Rationale for Nasal Allergen Challenge  
This study will use the NAC to assess the e fficacy of dupilumab with or without SCIT on 
allergic symptoms outside of grass allergy season.  The NAC is a well -recognized nasal 
provocation model that reproduces direct allergen contact of the upper airways in a controlled 
clinical setting allowing for  rapid proof -of-mechanism (POM) in smaller numbers of patients 
than natural exposure studies ( Eckman, 2010 ) (Paterniti, 2011 ).  Intranasal instillation of allergen 
causes local allergic sympt oms, such as nasal congestion, itching, sneezing and rhinorrhea, 
which peak within the first hour of the early phase reaction (EPR) ( Scadding, 2015a ).  Within 
minutes of local allergen exposure, IgE -mediated basophil and t issue mast cell degranulation 
occurs with the release of mediators, which cause blood vessel dilation and vascular leakage 
immediately leading to these nasal symptoms.  Therefore, the change in TNSS score after NAC 
with Timothy Grass extract is selected fo r POM as a reliable, reproducible, and controlled 
method of measuring allergy symptoms for this study.  Each subject will undergo a baseline 
NAC at screening and a repeat NAC at the end of treatment.  
3.2.7.  Rationale for Primary Endpoint  
As a primary endpoint, th e percent change in the AUC for TNSS (0 -1 hr post peak TNSS) in 
response to a NAC at week 17 from the pretreatment baseline TNSS AUC (0 -1 hr post peak 
TNSS) will be assessed for dupilumab in combination with SCIT vs SCIT monotherapy 
(+ placebo for dupiluma b).  During the up -titration phase of the NAC, TNSS will be measured 
every 10 minutes during the first hour until attainment of a TNSS score ≥ 7, and then TNSS will 
be measured at 5 minutes, 15 minutes, 30 minutes, 45 minutes, one hour, then hourly up to 
6 hours post -NAC.  Peak symptoms occur between 0 -1 hours after NAC, therefore the primary 
endpoint will measure the AUC of TNSS over the first hour after peak TNSS is achieved 
(Regeneron unpublished data).  A 20 -30% reduction in symptoms is considered a cli nically 
meaningful response ( Meltzer, 2016 ) (Pawankar, 2011 ).  Compared to natural exposure or 
environmental chamber, nasal provocation is a controlled and customized administration of 
allerg en, resulting in a more reliable and reproducible assessment of efficacy with a smaller 
sample size.  Additionally, environmental chamber studies are limited to one site as chambers at 
different sites vary considerably by allergen exposure.  
3.2.8.  Rationale for O ther Endpoints  
3.2.8.1.  Ratio of Allergen -Specific IgG4 to IgE in Serum  
Immunotherapy induces both cellular and humoral regulatory immune mechanisms.  Humoral 
mechanisms involve the induction of allergen specific antibodies, especially of the IgG4 isotype, 
which is  thought to have a protective effect against IgE -mediated allergic symptoms.  IgG4 
competes with IgE, blocking IgE -mediated effector cell activation, suppresses histamine release 
and inhibits antigen -presentation of IgE -allergen complex by dendritic and B -cells 
(James,  2012 ).  The gradual increase in serum allergen -specific IgG4, IgE -blocking factor and 
decrease in allergen -specific IgEs have been associated with clinical desensitization in SCIT for 
grass  (Shamji, 2012 ) and was consistently observed across different studi es.  At the start of 
SCIT, serum sIgG4s are low/undetectable.  In response to the initiation of SCIT, a 2 -fold 
increase in sIgG4 and a transient increase in sIgE is observed ( Scadding, 2017 ) (Creticos, 1992 ) 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 26 of 87 
CONFIDENTIAL  (Suarez -Fueyo, 2014 ).  An approximately 8 -fold increase in the ratio of sIgG4/sIgE was 
associated with a reduction in symptoms induced by nasal allergen provocation after 1 -year of 
SCIT ( Scadding, 2017 ).  A higher ratio of sIgG4/sIgE in patients tolerant to some allergens 
(eg, birch, cat, peanut) compared to their symptomatic controls was observed 
(Gero ldinger -Simic, 2011 ) (Du Toit, 2013 ) (Burnett, 2013 ).  Compared to the individual levels 
of sIgG4 or sIgE, the ratio of sIgG4/IgE is thought to be more reflective of the competition for 
allerge n binding between IgG4 and IgE and  has so far shown better correlation with clinical 
improvement.  Given that the induction of sIgG4 and the suppression of sIgE is the most well-
known  phenomenon associated with immunotherapy and dupilumab has been shown to  suppress 
specific IgE in past studies, we aim to test if skewing of sIgG4/IgE ratio will be one of the 
immunological effects of dupilumab as an adjunct to SCIT treatment.  
3.2.8.2.  Nasal: Early -Phase (0–60 min) and Late -Phase (6 hr) Reaction to Nasal Allergen 
Chall enge  
Response to nasal allergen challenge has been used as a surrogate for seasonal symptoms in past 
clinical trials of corticosteroid treatment for allergic rhinitis.  The concentration of 
cytokines/chemokines and other mediators in the nasal fluid were r ecorded as a measure of 
inflammatory response.  The early phase reaction (EPR) was characterized by the induction of 
tryptase and histamine, which were thought to reflect mast cell activation and degranulation in 
the nasal epithelium.  Existing data from m ultiple studies consistently reported peak induction of 
tryptase at 5 -minutes post challenge, followed by rapidly declining levels within 60 minutes and 
then dropping back to baseline within 2 hours.  The late phase reaction (LPR) is thought to 
reflect typ e 2 inflammation mediated by Th2 -cells and eosinophils that migrate to the site of 
inflammation.  The gradual increase in eosinophil cationic protein (ECP), eotaxin, eotaxin -3, 
IL-4, IL -5, IL -13, IFN IL-9 can be detected at pg/mL to ng/mL concentrations f rom 1 to 2 hours 
onwards.  Typically, Type 2 cytokine levels in nasal fluid also increase some hours after 
challenge: IL -5 at 6 –9 h ( Nicholson, 2011 ) (Linden, 2000 ); IL -13 at 6 –8 h ( Erin, 2005a ) 
(Nicholson, 2011 ); and IL -4 at 5 –6 h ( Wagenmann, 2005 ).  IL -10 was reported to increase in 
nasal fluid 6 hours post allergen challenge ( Bensch, 2002 ).  IFN -γ levels did not show significant 
induction in published studies, which is consistent with a primarily type 2 mediated 
inflammation following NAC ( Scadding, 2012 ).  
Allergen specific immunotherapy with Timothy Grass has been shown to decrease both the early 
phase and late phase reaction post -NAC, as measured by the decrease of tryptase, eotaxin, IL -9 
and IL -4 in the nasal fluid collected from patients on immunotherapy compared  to placebo 
(Scadding, 2015b ).  We hypothesize that dupilumab treatment as an adjunct to SCIT treatment 
may further suppress the tissue specific allergic response to allergen challenge, as well as further 
decrease the indu ction of type -2 cyotkines and chemokines in late phase reactions compared to 
SCIT alone.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 27 of 87 
CONFIDENTIAL  Two techniques could be used to collect and study mediators in nasal fluid.  Key considerations 
include acceptability to patients, collection of adequate volumes, and adequate concentration to 
allow the planned immunoassays.  Generally, techniques involving direct absorbance from the 
mucosa provide optimal results ( Klimek, 1999a ) (Klimek, 1999b ) (Lü, 2010 ) 
(Riechelmann,  2003 ).  In a comparison study by Scadding GW and colleagues, nasal sponges 
were shown to be superior to strip paper method (higher sample volume and statistically 
significant indu ction of ECP, IL -5, IL -13 were detected post NAC) ( Scadding, 2012 ).  In a 
Regeneron/Sanofi sponsored NP study with dupilumab, sufficient volumes of nasal fluid were 
collected by the sponge method and TARC, ECP and eotaxin -3 levels within detectable range for 
ELISA -based assays (Regeneron/Sanofi unpublished data), which also supports our selection of 
nasal sponge as the method of nasal fluid collection.  
3.2.8.3.  Skin: Early -Phase (0–60 min) and Late -Phase (6 hr) Skin Reaction to Allergen 
Challenge   
The SPT with serial allergen titration assesses the early phase reaction (EPR) at 0 -60 min.  The 
intradermal allergen injection will be performed to assess late phase reaction (LPR) at 6 hours.  
The early phase reaction is characterized by  histamine release and  is thought to reflect cutaneous 
mast cell degranulation upon allergen exposure.  The allergen -induced cutaneous LPR is 
characterized by an influx of inflammatory cells, including basophils, eosinophils, activated 
CD4+ -cells, and neut rophils which arrive at the site of inflammation some hours after 
provocation.  
Allergen specific immunotherapy with Timothy Grass has been shown to decrease both the early 
phase reaction after SPT, and late phase reaction after intra -dermal allergen chall enge, as 
measured by the decrease of wheal size post challenge ( Scadding, 2015b ).  In addition, short 
term grass SCIT treatment (13  weeks) led to significant and lasting reduction of LPR with 
statistical significance 12  months after the end of SCIT ( Chaker, 2015a ) (Chaker, 2015b ).  We 
hypothesize that dupilumab as an adjunct to SCIT treatment may further reduce skin allergic 
response to Timothy Grass and  can further decrease LPR compared to SCIT alone.  Based on 
expected reduction of IgE levels 12  weeks after dupilumab treatment in past AD studies, a 
reduction in mast cell activation may result in reduction in EPR and therefore reduced wheal 
sizes may als o be expected.  
3.2.8.4.  Serum TARC and Total IgE  
Serum TARC and total IgE are markers of Type 2 immune activity.  Dupilumab significantly 
suppressed both TARC and total IgE in studies of adult AD, NP, and asthma patients.  
3.2.8.5.  Basophil Sensitivity Test for Timothy Gras s 
The allergen -specific decrease in basophil sensitivity following SCIT has been described for 
olive pollen allergy, birch pollen allergy and Timothy Grass allergy ( Gokmen, 2012 ) 
(Lalek,  2010 ) (Nopp, 2009 ).  In a 40 -patient, 15 -month, placebo -controlled study for allergic 
rhinitis, patients who received either SLIT or SCIT for Timothy Grass, basophil sensitivity for 
Timothy Grass was shown to decrease as early as one month after SCIT treatment and continues 
to decline at 15 -months ( Aasbjerg, 2014 ).  In the above study, basophil activation was measured 
by high CD203 expression and high percentage of CD63+ cells.  Basophil sensitivity was  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 28 of 87 
CONFIDENTIAL  measured by the concentration of allergen (ng/mL), sufficient to give a 50% of maximal 
activation (EC50) ( Aasbjerg, 2014 ).  For the current study of dupilumab as an adjunct for grass 
SCIT study, instead of EC50, basophil s ensitivity will be measured by the threshold 
concentration of Timothy Grass sufficient to activate basophils in patient whole blood.  
Basophil and mast cell activation are critical steps in mediating immediate allergic symptoms 
upon allergen exposure.  The activation of basophil and mast cells is an IgE -mediated event, 
where cross -linking of grass -specific IgEs bound to high affinity Fc (epsilon) receptors on mast 
cells and basophils trigger immediate degranulation.  In a study investigating the biomarker 
profile of dupilumab in patients with AD (Regeneron unpublished data) as well as other 
dupilumab studies, dupilumab suppressed both total and allergen -specific IgEs.  In general, 
dupilumab suppresses total IgE by ~50% with 12 to 16 weeks of treatment.  Based  on the 
anticipated effect of dupilumab in reducing IgE, we hypothesize that dupilumab  + grass SCIT 
may further reduce basophil sensitivity over grass SCIT alone.  This improvement could be 
linked to allergic symptom reduction during dupilumab treatment as  an adjunct for grass SCIT.  
The exploratory basophil sensitivity testing will not be reported in the clinical study report.  
3.2.8.6.  Frequency of Circulating Th2A Cells  
One important area of investigation is to determine the effect of dupilumab as an adjunct to SCIT 
treatment on changes in allergic T -cell responses.  At week 4 (300mg/QW or Q2W) dupilumab 
effectively reduced CD3+ T -cells in AD skin lesions and suppressed Th2 inflammatory pathways 
genes (eg, CCL13, CCL17 and CCL18), as shown by past studies in atop ic dermatitis 
(Hamilton,  2014 ).  These data indicate that dupilumab has direct suppressive effect on Th2 cells.  
However, due to the extreme low frequency of allergen -specific T -cells in circulation, 
conventional immunophen otyping of Th2 cells has not been successful in capturing changes in 
allergen -specific T -cells during specific immunotherapy.  Th2A cells are allergen -specific Th2 
cells with a characteristic surface marker signatures (CRTH2+, CD27−, CD154+, CD161+, 
CD45RB −, and CD49d+ ( Wambre, 2017 ).  Using these markers, Wambre et al. reported a 
significant reduction in the frequency of pro -allergic Th2A cell subsets from subjects receiving 
active grass tablets (SLIT) compared to those recei ving placebo.  This method has also been 
implemented in assessing changes in allergen specific T -cells in a 2 -year longitudinal grass 
immunotherapy study performed by the Immune Tolerance Network, where frequency of 
allergen -specific Th2 cells paralleled c linical outcomes ( Renand, 2017 ) .Therefore, monitoring 
allergen -specific Th2 cells may reveal important mechanistic insight into the amelioration of 
allergic symptoms by dupilumab as an adjunct to SCIT treatment.  
The explorat ory Th2A analyses will not be reported in the clinical study report.  
3.2.8.7.  Type 2 Inflammation in the Nasal Mucosa in Response to a NAC as Measured 
by RNA Sequence and Gene Expression Analysis  
The sponsor hypothesizes that dupilumab may suppress the homing of eosinophils and Th2 -cells 
to the tissue, thus reducing the induction of genes and inflammatory pathways associated with 
type 2 inflammation post NAC.  Existing data in the literature suggest that type 2 inflammation 
in asthmatic or allergic rhinitis patien ts could be detected by gene expression analysis of nasal 
tissue samples, collected either by nasal brushing or nasal curettes.  For instance, RNA 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 29 of 87 
CONFIDENTIAL  expression analysis of type 2 -associated genes in nasal brushings from 50 asthmatic patients and 
50 healthy c ontrols have identified "Th2 -high" and "Th2 -low" subjects differentiated by the 
expression of 70 genes associated with type 2 pathways, including IL -13, IL -5, and periostin. 
The analysis also revealed that Th2 -high subjects were more likely to have atopy, atopic asthma, 
higher blood eosinophil counts and rhinitis, compared with Th2 -low subjects.  Nasal IL -13 
expression was 3.9 -fold higher in asthmatic participants who experienced an asthma 
exacerbation in the past year ( Poole, 2014 ).  In a study of allergic rhinitis patients treated with 
prednisone or placebo, nasal challenge with Timothy Grass was performed.  Eight hours post 
NAC, significant increases in eosinophil related gene -expression were detected in the nasal 
sampling of  placebo -treated patients compared to baseline, but not in prednisone -treated patients 
(Leaker, 2017 ).  These data suggest that transcriptome analysis of nasal brushings could be used 
to assess underlying type 2 -driven inflam mation.  
The exploratory nasal secretion and brushing analyses will not be reported in the clinical study 
report.  
3.2.8.8.  Rationale for Study Duration  
The time course of SCIT efficacy is not well established with limited data published regarding 
short -term efficacy  endpoints.  Clinical guidelines and experience indicate that symptomatic 
improvement can be demonstrated shortly after the patient reaches a maintenance dose 
(Ewbank,  2003 ).  It is thought the onset of action could coincide with induction of sIgG4, which 
plateaus after reaching maintenance dose.  While conventional up -dosing schedules require 8 -
12 weeks, we propose an 8 -week cluster up -titration regimen to accelerate time to maintenance 
dose and onset of action of SCIT.  Dupi lumab has resulted in rapid, potent suppression of type 2 
biomarkers within 4 -12 weeks of treatment in all indications tested to date.  Thus, a 16 week 
treatment duration is expected to be sufficient to evaluate the effects of dupilumab with and 
without SC IT. 
4. STUDY VARIABLES  
4.1. Demographic and Baseline Characteristics  
Baseline characteristics will include standard demography (eg, age, race, weight, height, 
co-morbid atopic conditions, years with aeroallergen disease, sex, etc), disease characteristics 
includin g medical history, and medication history for each subject.  
4.2. Primary and Secondary Endpoints  
4.2.1.  Primary Endpoint  
The primary endpoint is the percent change in AUC for TNSS (0 -1 hr post peak TNSS) in 
response to a NAC at week 17 from the pretreatment baseline T NSS AUC (0 -1 hr post peak 
TNSS) for dupilumab + SCIT as compared to placebo +SCIT monotherapy.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 30 of 87 
CONFIDENTIAL  4.2.2.  Secondary Endpoints  
 Change from baseline in TNSS AUC post NAC over the first hour after the challenge 
(0-1 hr post peak TNSS) at week 17 for dupilumab + SCIT as compared to SCIT 
monotherapy  
 Change and percent change from baseline in TNSS AUC post NAC over the first 
hour of the challenge (0 -1 hr post peak TNSS) at week 17 for dupilumab 
monotherapy as compared to placebo  
 Change and percent change from baseline in th e TNSS AUC post NAC over the first 
hour of the challenge (0 -1 hr post peak TNSS) at week 17 for dupilumab + SCIT as 
compared to dupilumab + placebo for SCIT.  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in serum Timothy Grass sIgG4 for dupilumab + SCIT as compared to SCIT 
monotherapy  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in serum  Timothy Grass sIgE  for dupilumab + SCIT as compared to SCIT 
monotherapy  
 Change from baseline (last pretreatment measurement) to week  17 in log -transformed 
value of serum Timothy Grass sIgG4 to Timothy Grass sIgE ratio  for dupilumab + 
SCIT as compared to S CIT monotherapy  
 Incidence rates of treatment -emergent adverse events (TEAEs) and serious TEAEs 
through end of study  
4.2.3.  Exploratory Endpoints  
 Change and percent change from baseline in the peak TNSS at week 17 for 
dupilumab + SCIT as compared to SCIT monothera py and for dupilumab 
monotherapy as compared to placebo  
 Change and percent change from baseline in TOSS AUC post NAC over the first 
hour of the challenge (0 -1 hr post peak TNSS) at week 17 for dupilumab + SCIT as 
compared to SCIT monotherapy and for dupil umab monotherapy as compared to 
placebo  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in Skin Prick Test with Serial Allergen Titration, as measured by AUC of the 
wheal sizes (diameter) over the course of 0 hour to hour 1 after the challenge (early 
phase reaction)  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in the wheal size (diameter) induced by skin Timothy Grass intradermal 
injection 6 hrs after the challenge (late phase reac tion)  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in PNIF AUC over the course of 0 hour to hour 1 and hour 1 to hour 6 after 
the challenge (early and late phase reaction)  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 31 of 87 
CONFIDENTIAL   Change and percent change from baseline (last  pretreatment measurement) to 
week  17 in sneeze count AUC over the course of 0 hour to hour 1 and hour 1 to hour 
6 after the challenge (early and late phase reaction)  
 Change and percent change from baseline (last pretreatment measurement)  to 
week  17 in ser um TARC  
 Change and percent change from baseline (last pretreatment measurement) to 
week  17 in serum total IgE  
4.3. Pharmacokinetic Variables  
Concentration of functional dupilumab in serum at each time point, obtained prior to dosing, will 
be measured (C trough) 
4.4. Anti -Drug Antibody Variables  
Anti-drug antibody variables include ADA status and titer as follows:  
 Total subjects with treatment emergent response  
 Treatment emergent - defined as a positive response in the ADA assay post first dose 
when baseline results are negative.  
 Total subjects with treatment boosted response  
 Treatment boosted – defined as a positive response in the ADA assay post first dose 
that is greater than or equal to 4 -fold over baseline titer levels, when baselines results 
are positive.  
Sample s positive in the ADA assay will be assessed for titer:  
 Titer category  
o Low (titer <1,000)  
o Moderate (1,000 ≤ titer ≤10,000)  
o High (titer >10,000)  
5. STUDY DESIGN  
5.1. Study Description and Duration  
This is a Phase 2a, multicenter, randomized, double -blind, parallel group, 4 -arm study of 
dupilumab as an adjunct to grass SCIT and consists of a 12 week screening period, 16 week 
treatment period and a 8 week post treatment follow -up period in subjects with a history of 
allergic rhinitis to grass pollen.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 32 of 87 
CONFIDENTIAL  5.1.1.  Dosing and Admini stration  
5.1.1.1.  Dupilumab or Dupilumab Placebo  
Dupilumab will be administered SC, as a 600 mg loading dose and then 300  mg Q2W.  
Dupilumab 150 mg/mL:  Each single -use, pre -filled glass syringe with snap -off cap delivers 
2.0 mL of a 150 mg/mL solution (300 mg).  
Placebo matching dupilumab is prepared in the same formulation without the addition of protein 
(ie, active substance, anti -IL-4Rα monoclonal antibody).  
After the loading dose, subjects will have the option to administer dupilumab or dupilumab 
placebo (or have a caregiver administer it) outside the study site.  The study staff will train the 
subject/caregiver on preparation and administration of dupilumab or dupilumab placebo on day 1 
and will administer the first 2 injections required for the loading dose.   Subjects will be 
monitored at the study site for a minimum of 30 minutes after the first 2 doses of dupilumab or 
dupilumab placebo (loading dose) and blood pressure and heart rate determined.  The subject (or 
caregiver) will administer dupilumab or dupil umab placebo outside of the study site during 
subsequent weeks of the study.  
Subjects who prefer to have the study site staff administer dupilumab or dupilumab placebo may 
choose to have injections administered in the study site.  
The procedure for preparin g the dupilumab or dupilumab placebo dose for SC injection will be 
provided in the pharmacy manual.  Subcutaneous injection sites should be alternated among the 
different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper 
arms, so that the same site is not injected for 2 consecutive weeks.  To allow for adequate 
assessment of possible injection site reactions (ISRs), dupilumab or dupilumab placebo should 
be administered only into areas of normal -looking skin.  Instructions fo r recording and reporting 
ISRs will be provided in the study reference manual.  
Detailed instructions for transport, storage, preparation, and administration of dupilumab or 
dupilumab placebo will be provided by the site to the subject (or caregiver).  Subj ects will 
complete a dosing diary to document compliance with self -injection of dupilumab or dupilumab 
placebo outside the study site.  
5.1.1.2.  SCIT and Placebo Matching SCIT  
SCIT will be up -dosed for 8 weeks to a 4,000 BAU dose, followed by an 8 -week maintenance 
dose.  (See Table  1 for SCIT schedule).  
Placebo matching SCIT is prepared in the same formulation (SCIT diluent) without the addition 
of Timothy Grass extract.  
All SCIT visits will be supervised in an in -clinic study site setting where trained study 
physicians, who are experts in Allergy and Immunology and who are experienced SCIT 
providers, are present.  Subjects will be observed for at least 30 minutes  after any SCIT injection.  
Standing orders from a study physician will be provided for all clinical study personnel to 
immediately (ie, prior to study physician notification) initiate treatment of reactions, including 
but not limited to intramuscular admi nistration of epinephrine, based on their own clinical 
judgment.  For all SCIT visits subjects must be pre -medicated with an H1 anti -histamine 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 33 of 87 
CONFIDENTIAL  (loratadine 10 mg orally) 1 -6 hours prior to each injection visit, as recommended by clinical 
guidelines to reduc e local and systemic reactions during the cluster SCIT.  ( Cox, 2011 ) 
(Nielsen,  1996 ).  Loratadine will be supplied to study sites as a non -investigational medicinal 
product (NIMP).  
Figure  1: Study Flow Diagram  
 
*The NAC happens after 16 weeks of study treatment at week 17.  
5.2. Screening  
After obtaining informed consent, subjects will be assessed for eligibility during a 3 -part 
screening period.  The 3 -part screening period is up to 12 weeks.  As this is an off -season study 
that must begin and end outside of grass season, sufficient screening time is necessary so that 
subjects may be enrolled efficiently.  During screening visit 1, subjects with a history of allergic 
rhinitis to grass pollen will undergo a medical history, physical examination, SPT for Timothy 
Grass, and blood draw for Timothy Grass specific IgE.  If the subject meets criteria with a 
positive SPT for Timothy Grass and for Timothy Grass specifi c IgE as per Inclusion/Exclusion 
criteria, they will be invited for screening visit 2.  At screening visit 2 they will undergo a 
pregnancy test if applicable, spirometry, electrocardiogram (ECG), serologic testing for chronic 
viral infections (Human Immuno deficiency Virus Infection [HIV] and Hepatitis B and C), 
hematology, chemistry, urinalysis, will be evaluated for the study eligibility criteria, and will 
undergo a baseline nasal brushing.  The baseline nasal brushing must occur while TNSS≤2 and it 
must b e at least 28 days prior to the screening visit 3/Entry visit, so that the nasal mucosa may 
re-epithelialize and return to a resting state prior to NAC.  If the subject reports nasal symptoms 
and has a TNSS>2 at Screening visit 2, they can be rescheduled f or screening visit 2 when they 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 34 of 87 
CONFIDENTIAL  are no longer symptomatic - for re -evaluation by TNSS.  The baseline nasal brushing should not 
be performed if the 28 day waiting period until the NAC will compromise the subject’s ability to 
complete the 16 week treatment per iod and final week 17 NAC prior to the subsequent allergy 
season (eg, subjects cannot have any expected seasonal or environmental allergic symptoms at 
the week 17 NAC visit).  If however, the full 16 week treatment period and week 17 NAC visit is 
expected to be completed prior to the subsequent allergy season, subjects should undergo 
baseline nasal brushing.  Forgoing the baseline nasal brushing in this case will not be considered 
a protocol deviation, but the event will be recorded and justified.  It is ex pected that subjects who 
are enrolled in the final month of the enrollment period, as described in the Study Operations 
Manual, will not undergo the baseline nasal brushing.  
At screening visit 3/Entry visit (day -1), subjects may not have taken anti -histam ines for at least 
5 days.  If the subject reports having taken anti -histamines within 5 days of Screening visit 3, 
they can be rescheduled for Screening visit 3.  
At screening visit 3/Entry visit, subjects will be observed for approximately 10 minutes and a  
resting/baseline TNSS≤2 must be achieved, signifying that the subject does not have active nasal 
symptoms at rest (due to viral infection, sinusitis, allergies, etc.), prior to NAC.  If the subject 
has a TNSS>2, signifying that they have active nasal symp toms at rest, they can be rescheduled 
for Screening visit 3.  TNSS (measured on a 0 -12 scale) is a composite symptom assessment of 
congestion, itching, rhinorrhea (each graded on 0 -3 scale, 3 being severe), and sneezing (2 being 
3-4 sneezes and 3 being >5 sneezes).  TNSS report will be included in the Study Operations 
Manual.   
If the subject has a resting/baseline TNSS  ≤2 and therefore has no appreciable nasal symptoms at 
rest, a NAC and skin testing for early and late phase reactions will be performed as follows:  
 NAC will be performed using increasing doses of Timothy Grass extract every 
10 minutes up to 1 hour (up -titration phase), or until a TNSS ≥7 is reached.  An 
example of concentrations are as follows:  14 BAU/ml, 41 BAU/ mL, 123 BAU/ mL, 
370 BAU/ mL, 1111 BAU/ mL, and 3333 BAU/ mL; please refer to the study manual 
for exact concentrations.  
 The peak TNSS will be recorded.   
 The Timothy Grass extract concentration that was used to attain TNSS ≥7 must be 
recorded .   
 Subjects will be observed for the subsequ ent hour and the TNSS will be recorded at 
5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, and then hourly up to 6 hours.   
 In addition to TNSS, the following will be measured at baseline, approximately every 
10 minutes during the up -titration phase,  and during the subsequent hour after peak 
TNSS is achieved (at 5 minutes, 15 minutes, 30 minutes, 45 minutes, and 1 hour) and 
hourly up to 6 hours:  
o PNIF; (measured in nasal patency, L/min)  
o Total sneezes  
o TOSS  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 35 of 87 
CONFIDENTIAL  Grass allergic subjects will be eligible for  enrollment based on having a TNSS ≤2 prior to the 
screening NAC (time 0), peak TNSS ≥7 within the first hour during the up -titration phase. 
Additionally for eligibility, between the first non -zero dose of and approximately 10 minutes 
after the highest/pea k dose, subjects must experience either a >20% drop in PNIF or >/=3 
sneezes must be counted.  
5.3. Randomized Treatment Period (16 Weeks)  
5.3.1.  Randomization  
A total of 100 adult subjects with a history of allergic rhinitis to grass pollen who successfully 
complete sc reening procedures will be randomized 1:1:1:1 into the 4 treatment arms (n=25 in 
each arm) as follows:  
1. SCIT up -titrated as described up to a 4,000 BAU maintenance dose + dupilumab 
(SC 300 mg Q2W, after 600 mg loading dose)  
2. SCIT up -titrated as described up  to a 4,000 BAU maintenance dose + placebo for 
dupilumab  
3. Placebo for SCIT plus dupilumab (SC 300 mg Q2W, after 600 mg loading dose)   
4. Placebo for SCIT plus placebo for dupilumab  
Note:  Randomization (visit 4) must occur within 2 weeks after NAC (visit 3)  
5.3.2.  Study Design Safety Considerations for SCIT  
 All SCIT visits will be supervised in an in -clinic study site setting where trained study 
physicians are available.  
 Subjects will be observed for at least 30 minutes after any SCIT injection.  
 Standing orders from a study physician will be provided for all clinical study 
personnel to immediately (ie, prior to study physician notification) initiate treatment 
of reactions, including intramuscular administration of epinephrine, based on their 
own clinical judgment.  
 A crash cart will be available in close proximity (within 50 feet) of all patient study 
site rooms.  
 On days when SCIT or placebo SCIT are given, subjects must be pre -medicated with 
an H1 anti -histamine (loratadine 10 mg orally) 1 -6 hours prior to each injecti on visit, 
as recommended by clinical guidelines to reduce local and systemic reactions during 
cluster SCIT ( Cox, 2011 ) (Nielsen, 1996 ).  Loratadine will be supplied to study sites 
as a NIMP.  
 Patients will be dosed Q2W SC with dupilumab or placebo for dupilumab on separate 
days from the study -site SCIT or placebo for SCIT dose escalation.  
 SCIT dosing related allergic symptoms and adverse events will be captured 
throughout the study.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 36 of 87 
CONFIDENTIAL  5.4. Post-Treat ment Follow -up Period (8 Weeks):  
All subjects who complete or prematurely discontinue the treatment will be assessed for safety, 
laboratory, and clinical assessments as noted in the Schedule of Events ( Table  3) 8 weeks after 
the end -of-treatment.  
The duration of the 8 -week follow -up period is based on the time expected for drug 
concentrations to approach the lower limit of quantification after the las t dose of dupilumab . 
5.5. End of Study Definition  
The end of study is defined as the last visit of the last subject.   
5.6. Planned Interim Analysis  
No interim analysis is planned.  An unblinded first -step analysis may be performed once all 
subjects in the study hav e completed the 16 -week treatment period and performed NAC at 
week  17 as specified in the protocol ( visit 16 or earlier for those subjects who are withdrawn 
prematurely from the study).  If performed, this first -step analysis will be considered the final 
analysis for the primary endpoint and secondary efficacy endpoints up to end of treatment NAC 
visit 16 (week 17).  A description of the statistical methods to be employed and blinding 
implications are in Section  10.4.3.4 . 
6. SELECTION, WITHDRAWA L, AND REPLACEMENT O F SUBJECTS  
6.1. Number of Subjects Planned  
Approximately 100 subjects will be randomized (25 per treatment group) at approximately 
20 planned sites in North America in geographies where Timothy Grass is the relevant grass 
species.  
6.2. Study Population  
6.2.1.  Inclusion Criteria  
A subject must meet the following criteria to be eligible for inclusion in the study:  
1. Male and female subjects aged 18 to 55  
2. History of grass pollen –induced seasonal allergic rhinitis  
3. Grass pollen allergy confirmed by both:  
a. Positive SPT with Timothy Grass extract (mean wheal d iameter at least ≥5 mm 
greater than a negative control)  
b. Positive serum Timothy Grass -specific IgE (≥0.35KU/L)  
4. Positive NAC with Timothy Grass extract at screening with peak TNSS score ≥7 out of 
12 
5. Between the first non -zero dose and approximately 10 minute s after the highest dose of 
NAC, participants must experience either a >20% drop in PNIF or >/=3 sneezes must be 
counted  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 37 of 87 
CONFIDENTIAL  6. Provide informed consent signed by study subject  
7. Able to understand and complete study -related questionnaires  
8. Willing and able to compl y with study site visits and study -related procedures  
6.2.2.  Exclusion Criteria  
A subject who meets any of the following criteria will be excluded from the study:  
1. Significant rhinitis (causing TNSS  >2), sinusitis, outside of the grass pollen season, or 
due to dai ly contact with other allergens causing symptoms that is expected to coincide 
with the baseline or the final NAC assessments as assessed by the investigator  
2. Subjects who anticipate major changes in allergen exposure in their home or work 
environments that are expected to coincide with  the baseline or the final NAC 
assessments as assessed by the investigator  
3. At screening NAC, current symptoms of, or treatment for, upper respiratory tract 
infection, acute sinusitis, acute otitis media, or other relevant infec tious process; serous 
otitis media is not an exclusion criterion.  Participants may be re -evaluated for eligibility 
after symptoms resolve.  
4. Any contraindications to SCIT (ie, severe cardiovascular disease, malignancies, 
autoimmune disease, use of beta bloc ker, asthma severe enough to require chronic 
medication, acute infection)  
5. Patients with any laboratory findings showing evidence of organ dysfunction or any 
clinically significant deviation from the normal range, as decided by the investigator at 
the screening visit, including but not limited to:  
 Clinically significant/active underlying hepatobiliary disease.  
OR, 
 Alanine aminotransferase (ALT) >3 upper limit of normal (ULN).  
Abnormal laboratory values at screening:  
 Creatine phosphokinase (CPK) >10 ULN  
OR, 
 Platelets <100 000 cells/mm3. 
OR, 
 Eosinophils >1500 cells/mm3. 
6. Use of any concomitant medications within the following time period preceding any 
screening visit or any screening NAC visit ( visit 3) including antihistamines (5 days), 
leukotriene inhibitors (7 days), mast cell inhibitors (7 days), intranasal corticosteroids 
and/or inhaled corticosteroids (14 days), oral or topical decongestants (5 days), topical 
calcineurin inhibitors (4 weeks), beta blockers (5 days). Participants may be re -evalua ted 
for eligibility after the time period for taking these concomitant medications has passed.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 38 of 87 
CONFIDENTIAL  7. Use of systemic corticosteroids within 4 weeks of screening visits or any NAC visits  
8. Abnormal lung function as judged by the investigator with FEV 1<80% of predic ted  
9. A clinical history of asthma requiring chronic medication such as regular inhaled 
corticosteroids for >4 weeks per year  
10. A clinical history of asthma with 2 or more asthma exacerbations requiring 
hospitalizations or systemic corticosteroids in the pre vious year  
11. History of emergency visit or hospital admission for asthma in the previous 12 months  
12. History of significant recurrent sinusitis, defined as 3 episodes per year for the last 
2 years, all of which required antibiotic treatment  
13. History of chronic sinusitis (with or without nasal polyps) as defined as:  
presence of 2 or more symptoms one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip):  
 ± facial pain/pressure;  
 ± reduction or loss of smell;  
 for ≥12 weeks;  
14. Any gross mechanical nasal obstruction, or history of nasal or sinus surgery that would 
interfere with the conduct of the NAC, as per judgment of the investigator  
15. Tobacco smoking (ANY) within the last year   
16. Any history of grade 4 ana phylaxis due to any cause as defined by the Common 
Terminology Criteria for Adverse Events (CTCAE) grading criteria for immunotherapy 
(Appendix  1) 
17. History of chronic obstructive pulmonary disease  
18. History of other chronic disease (other than asthma, atopic dermatitis, allergic rhinitis) 
requiring therapy (eg, heart disease, diabetes, hypertension) that, in the opinion of the 
investigator, would repre sent a risk to the subject’s health or safety in this study or the 
subject’s ability to comply with the study protocol  
19. History of previous allergy immunotherapy (SCIT, sublingual immunotherapy, or oral 
immunotherapy) in the last 5 years  
20. Any previous exposure to dupilumab  
21. Treatment with an investigational drug within 2 months or within 5 half -lives (if known), 
whichever is longer, prior to screening  
22. Member of the clinical site study team or his/her immediate family  
23. Known or suspected immunosuppressio n, including history of invasive opportunistic 
infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, 
pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent 
infections of abnormal frequency, or prolonged  infections suggesting an 
immune -compromised status, as judged by the investigator  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 39 of 87 
CONFIDENTIAL  24. History of patient -reported alcohol or drug abuse within 6 months prior to screening  
25. History of bleeding disorders or treatment with anticoagulation therapy  
26. Subjects tested positive for HIV antibody, Hepatitis B surface antigen, or Hepatitis C 
antibody  
27. Use of anti -IgE therapy within 6 months prior to screening.  
28. Treatment with a live (attenuated) vaccine within 3 months prior to screening and during 
the study.  
29. Active chroni c or acute infection requiring systemic treatment with antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to the screening visit. 
NOTE:  subjects may be rescreened after the infection resolves.  
30. History of malignan cy within 5 years before the screening visit, except completely 
treated in situ carcinoma of the cervix, completely treated and resolved non -metastatic 
squamous or basal cell carcinoma of the skin.  
31. Established diagnosis of a primary immunodeficiency disor der (eg, Severe Combined 
Immunodeficiency, Wiskott Aldrich Syndrome, DiGeorge Syndrome, X -linked 
Agammaglobulinemia, Common Variable Immunodeficiency), or secondary 
immunodeficiency eg, HIV.  
32. Pregnant or breastfeeding women, women planning to become pregnant or breastfeed 
during the study  
33. Women of child bearing potential* who are not sexually abstinent and are unwilling to 
practice highly effective contraception prior to the initial dose/start of the first treatment, 
during the study, and for at least  12 weeks after the last dose.  Highly effective 
contraceptive measures include:  
a. stable use of combined (estrogen and progestogen containing) hormonal 
contraception (oral, intravaginal, transdermal) or progestogen -only hormonal 
contraception (oral, injecta ble, implantable) associated with inhibition of ovulation 
initiated 2 or more menstrual cycles prior to screening;  
b. intrauterine device (IUD); intrauterine hormone releasing system (IUS);  
c. bilateral tubal ligation;  
d. vasectomized partner;  
e. and or sexual abst inence †, ‡. 
*Postmenopausal women must be amenorrheic for at least 12 months in order not to 
be considered of childbearing potential.  Pregnancy testing and contraception are 
not required for women with documented hysterectomy or tubal ligation.  
†Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study treatments.  The reliability of sexual abstinence needs to be evaluated 
in relation to  the duration of the clinical trial and the preferred and usual lifestyle of 
the subject.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 40 of 87 
CONFIDENTIAL  ‡Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhoea method (LAM) 
are not acceptable methods of contraception. Female condom and male condom 
should not be used together.   
34. Subjects unable to understand and comply with clinical protocol  
35. Planned or anticipated use of any prohibited medications and procedures (as detailed 
in Section  7.7.1 ) during study treatment  
36. Adults lacking capacity to consent themselves into the study.  
6.3. Premature Withdrawal from the Study  
A subject h as the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or sponsor have the right to withdraw a subject from the study if it is no 
longer in the interest of the subject to continue in the study, or if the subject’s continuation in the 
study places the scientific outcome of the study at risk (eg, if a subject does not or cannot follow 
study procedures).  An excessive rate of withdrawals would render the study uninterpretable; 
therefore, unnecessary  withdrawal of subjects should be avoided.  
Subjects who are withdrawn prematurely from the study treatment will be asked to complete 
study assessments, as described in Section  8.1.2 . 
Rules for discontinuation of study treatment (permanent or temporary) are discussed in 
Section  7.3.2 . 
6.4. Replacement of Subjects  
Subjects prematurely discontinued from study drugs (SCIT or placebo for SCIT and dupilumab 
or placebo for dupilumab) will not be replaced.  
7. STUDY TREATMENTS  
7.1. Investigat ional and Reference Treatments  
7.1.1.  Dupilumab Injection:  Investigational Treatment  
Dupilumab at 300 mg Q2W with loading dose of 600 mg or equivalent placebo will be started on 
the day of randomization.  Dupilumab will be dosed as follows:  subjects will be giv en a loading 
dose of 600 mg dupilumab SC or placebo, followed by 300 mg Q2W SC for a total of 16  weeks.  
Dupilumab 150 mg/mL: Each single -use, prefilled glass syringe with snap -off cap delivers 
300 mg of study drug (2.0 mL of a 150 mg/mL solution) . 
Placebo matching dupilumab is prepared in the same formulation without the addition of protein 
(ie, active substance, anti -IL-4Rα monoclonal antibody).   The matching placebo formulation will 
be used:  2 mL placebo matching 300 mg dupilumab formulation . 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 41 of 87 
CONFIDENTIAL  Subcutaneou s injection sites of dupilumab or placebo for dupilumab should be alternated among 
the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper 
arms so that the same site is not injected for 2 consecutive administrations . 
Instructions on dose preparation are provided in the pharmacy manual.  
7.1.2.  Timothy Grass SCIT:  Reference Treatment  
Timothy Grass SCIT will be given using cluster dose escalation regimen over 8  weeks then 
maintenance therapy will be given described below. SCI T will be started no earlier than 1 day 
after the dupilumab loading dose and up to 1 week after the dupilumab loading dose.  Dosing of 
dupilumab should never be performed on the same day and administration site as SCIT.  
The Grass SCIT protocol will compris e 1-3 SC injections per week visit of allergen following 
the up -titration regimen described below over 8 weeks followed by the maintenance SC 
injections for the following 8 weeks as shown in Table  1.  The recommended target maintenance 
dose for SCIT is 4,000 bioequivalent allergy units (BAU) ( Table  1), which is equivalent to 
approximately 20 mcg Phlem Pratense 5  (major Timothy Grass allergen) ( Cox, 2011 ) 
(Frew,  2006b ).  During week s 1-3 of the up -dosing phase, 3 doses of SCIT will be given per 
visit: the first (lowest dose for that visit) will be given, the subject will be monitored for 30 
minutes, and if the dose is well tolerated, the next higher scheduled dose for that visit will  be 
given.  The subject will then be monitored for the next 30 minutes, and if the dose is well 
tolerated, the next higher scheduled dose for that visit will be given.  During weeks 4 -5 of the 
up-dosing phase, 2 doses of SCIT will be given: the first (lowe st dose for that visit) will be 
given, subject will be monitored for 30 minutes, and if the dose is well tolerated, the next higher 
scheduled dose for that visit will be given.  During weeks 6 -8 of the up -dosing phase, 1 dose of 
SCIT will be given.  During  the maintenance phase, one dose will be given per visit as per 
Table  1.  
Placebo SCIT will be given in the same manner as the Grass SCIT, following th e same protocol, 
but instead of active agent, diluent will be given.  The Placebo SCIT will have an identical 
appearance to the Grass SCIT.  The first (lowest dose for that visit) will be given, the subject will  
be monitored for 30 minutes, and if the dose  is well tolerated, the next higher scheduled dose for 
that visit will be given.  
On days when SCIT or placebo SCIT are given, subjects must be pre -medicated with an H1 anti -
histamine (loratadine 10 mg orally) 1 -6 hours prior to each injection visit, as rec ommended by 
clinical guidelines to reduce local and systemic reactions during cluster SCIT.  ( Cox, 2011 ) 
(Nielsen, 1996 ).  Reactions associated with SCIT or SCIT placebo should be recorded as AEs 
(Section  9.5), and attributed to SCIT or SCIT placebo or as interpreted by the study investigator 
(Section  9.5). 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 42 of 87 
CONFIDENTIAL  Table  1: SCIT Up -Titration and Maintenance Regimen  
Week No  Injection No  Subcutaneous Dose of SCIT 
(BAU)  
1 1 1 
1 2 4 
1 3 10 
2 4 20 
2 5 40 
2 6 70 
3 7 100 
3 8 150 
3 9 250 
4 10 400 
4 11 700 
5 12 1000  
5 13 1500  
6 14 2000  
7 15 3000  
8 16 4000  
10 17 4000  
13 18 4000  
16 19 4000  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 43 of 87 
CONFIDENTIAL  7.1.3.  Timing of Dupilumab/placebo and SCIT/placebo  
Dupilumab dosing starts prior to SCIT dosing as shown in Table  2.  Dupilumab/placebo are 
never to be given on the same day as SCIT/ placebo.  
Table  2: Dosing Schedule for  Dupilumab/Placebo with Respect to SCIT/Placebo  
Dose  Dupilumab/Placebo1 SCIT/Placebo  
NAC    
Randomization (V4)  X2  
Week 1   X3, 5 
Week 2  X4 X5 
Week 3   X4, 5 
Week 4  X4 X5 
Week 5   X4, 5 
Week 6  X4 X5 
Week 7   X4, 5 
Week 8  X4 X5 
Week 9    
Week 10  X4 X5 
Week 11    
Week 12  X4  
Week 13   X4, 5 
Week 14  X4  
Week 15    
Week 16  X4 X5 
NAC    
1. Dupilumab/placebo dosing must given ± 3 days of the visit window.  
2. Dupilumab or placebo for dupilumab loading dose is given day of randomization.  Subsequent dupilumab/placebo dosing is 
given Q2W  
3. SCIT/placebo should be given 1 to 7 days following dupilumab/dupilumab placebo loading dose.  Subsequent SCIT/placebo 
dosing follows dosing regimen as depicted in Table  1.  
4. During week 2, week 4, week 6, week 10, and week 16, when both dupilumab/placebo and SCIT/placebo are given in the 
same week, SCIT/placebo and dupilumab/placebo are NOT to be given on the same da y (can be 1 day to 7 days apart) AND 
SCIT/placebo and dupilumab/placebo are to be given in a different anatomical location.  
5. For SCIT/placebo visits, subjects are to be premedicated with an antihistamine as described in Section  5.1.1.2 . 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 44 of 87 
CONFIDENTIAL  7.2. Rescue Treatments  
If required, subjects who experience allergic reactions will be treated with rescue treatment 
including but not limited to IM or SC administration of  epinephrine,  as determined by trained 
study staff .  Subjects may also take oral antihistamines as needed for allergic rhinitis symptoms 
during the course of the study, however oral antihistamines may not be used within 5  days prior 
to or during a visit fo r NAC or skin testing.  If subject uses oral antihistamines within 5 days 
prior to or during a visit for NAC or skin testing they must be rescheduled.   
7.3. Dose Modification and Study Treatment Discontinuation Rules  
7.3.1.  Dose Modification  
Dose modification of dupi lumab or dupilumab placebo is not allowed.   
Dose modification/reduction of SCIT is allowed for an individual subject according to the 
following specifications:  
Subjects who develop either local or systemic side effects after an up -dosing visit of SCIT 
may require administration of the same dose at the next visit, a dosage reduction at the next 
visit, or a planned series of visits to achieve the same dose, as determined by the principal 
investigator.  
If subjects develop side effects during the up -dosing ph ase of SCIT, such as repeated large 
immediate local reactions or grade 1 -2 systemic reactions requiring dosage adjustments, the 
principal investigator (PI), in consultation with the medical monitor, may decide to reduce the 
planned maintenance dose of SCIT  of 4000 BAU down to between 400 BAU and 4000 BAU but 
no lower than 400 BAU.  
7.3.2.  Study Drug Discontinuation (Dupilumab or Placebo for Dupilumab and SCIT or 
Placebo for SCIT)  
If one study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT) is 
discontinued, all study drugs (dupilumab or placebo for dupilumab and SCIT or placebo for 
SCIT) must be discontinued.  
Subjects  who permanently discontinue from study drug (dupilumab or placebo for dupilumab 
and SCIT or placebo for SCIT) and who do not w ithdraw from the study  will be asked to return 
to the study site within 2 weeks of stopping study drug (dupilumab or placebo for dupilumab and 
SCIT or placebo for SCIT), if possible, to undergo their end of treatment visit, including NAC.  
Anti-histamines may not be taken within 5 days of NAC.  
Subjects  who permanently discontinue from study drug (dupilumab or placebo for dupilumab 
and SCIT or placebo for SCIT) and who opt to withdraw from the study will be asked to 
complete study assessments as per end of t reatment visit immediately, within 2 weeks of 
stopping study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT),  if 
possible, including NAC, per Section  8.1.2 .  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 45 of 87 
CONFIDENTIAL  7.3.3.  Reasons for Permanent Discontinuation of Study Drug (Dupilumab or Placebo 
for Dupilumab and SCIT or Placebo for SCIT)  
Subjects will be permanently discontinued from study treatment in the event of:  
 Anaphylactic reaction to study drug (dupilumab or placebo for dupilumab and SCIT 
or placebo for SCIT)  
 Evidence of pregnancy  
 Any infection that:  
o Requires parenteral treatment with antibiotic, antifungal, antiviral, anti -parasitic, 
or anti -protozoal agent  
o Requires oral treatment wit h such agents for longer than 2 weeks  
o Is opportunistic, such as tuberculosis and other infections whose nature or course 
may suggest an immunocompromised status  
 Severe laboratory abnormalities, such as:  
o Neutrophil count ≤0.5 x 103/µL 
o Platelet count ≤50 x 103/µL 
o ALT and/or aspartate aminotransferase (AST) values >3 x ULN with total 
bilirubin >2 x ULN, excluding confirmed Gilbert’s Syndrome  
o Confirmed AST and/or ALT >5 x ULN (for more than 2 weeks)  
 Other reasons that may lead to the permanent discontinuation of study treatment 
include:  
o Certain AEs deemed related to the study drug (dupilumab or placebo for 
dupilumab and SCIT or placebo for SCIT) (eg, severe and prolonged ISRs) or 
study procedures  
7.3.3.1.  Reasons for Temporary Discontinuation of Study Drug (Dupilumab or  Placebo 
for Dupilumab and SCIT or Placebo for SCIT)  
Study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT) dosing may be 
temporarily suspended in the event of:  
 Clinically important laboratory abnormalities, such as:  
o Neutrophil count ≤1.0 x 103/µL but >0.5 x 103/µL 
o Platelet count ≤100 x 103/µL but >50 x 103/µL 
o CPK >10 ULN  
 Short -term, self -limiting conditions (eg, infections resolving spontaneously or 
requiring ≤2 weeks of oral anti -infective treatment), with the exception of upper 
respiratory infections  
 Other intercurrent illnesses  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 46 of 87 
CONFIDENTIAL  After the condition leading to suspension of dosing resolves, study treatment may resume.  
A decision to temporarily discontinue study drug (dupilumab or placebo for dupilumab and SCIT 
or placebo for SCIT) and/or to reinstitute study treatment should be discussed with the medical 
monitor.  The investigator may suspend study treatment at any time , even without consultation 
with the medical monitor if the urgency of the situation requires immediate action and if this is 
determined to be in the subject’s best interest.  However, the medical monitor should be 
contacted as soon as possible in any case  of study drug discontinuation.  Resumption of study 
treatment after temporary discontinuation requires consultation and agreement between the 
investigator and the medical monitor.  In the case of SCIT or placebo for SCIT, if it was 
temporarily discontinue d during the up -dosing phase, the investigator may need to modify the 
up-dosing regimen at his/her discretion and will inform the medical monitor of any modification 
of the up -dosing regimen.  
7.4. Management of Acute Reactions  
7.4.1.  Acute Injection Reactions  
7.4.1.1.  System ic Injection Reactions  
Emergency equipment and medication for the treatment of systemic reactions must be available 
for immediate use.  All systemic reactions must be reported as AEs (as defined in Section 9.4.1 ) 
and graded using the grading scales as instructed in Section  9.5.1 .   
Acute system ic reactions following  injection of either dupilumab/placebo or SCIT/placebo 
should be treated using clinical judgment to determine the appropriate response according to 
typical clinical practice.  
7.5. Method of Treatment Assignment  
Approximately 100 subjects will be randomized at baseline in a 1:1:1:1 ratio into one of 
4 treatment arms (n=25/arm) described in Section  5.3.1  according to a central randomiz ation 
scheme provided by an interactive voice response system (IVRS)/interactive web response 
system (IWRS) to the designated study pharmacist (or qualified designee).  
7.5.1.  Blinding  
With the exception of the designated study pharmacist(s)/designee at the study  site who prepares 
and gives the SCIT or SCIT placebo, and the provisions in Section  7.5.2  , this study will remain 
blinded to all individuals until the pre -specified unblinding to conduct the primary analyses.  
The designated study pharmacist(s)/designee at the study site who prepa res and gives the SCIT 
or SCIT placebo may not perform the NAC and nasal and skin assessments (outcome measures).  
For dupilumab and placebo for dupilumab, blinded study drug kits coded with a medication 
numbering system will be used.  In order to maintain  the blind, lists linking these codes with 
product lot numbers will not be accessible to individuals involved in study conduct.   
Dupilumab anti -drug antibody and drug concentration results will not be communicated to the 
sites, and the sponsor operational  team will not have access to results associated with patient 
identification until after the final database lock.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 47 of 87 
CONFIDENTIAL  7.5.2.  Emergency Unblinding  
Unblinding of treatment assignment for a subject may be necessary due to a medical emergency 
or any other significant med ical event (eg,  pregnancy).  
 If unblinding is required:  
 Only the investigator will make the decision to unblind the treatment assignment.  
 Only the affected subjects will be unblinded.  
 The designated study pharmacist(s)/designee at the study site will provid e the 
treatment assignment to the investigator.  If there is no study pharmacist, the 
investigator for the site will unblind the subject  
 The investigator will notify Regeneron and/or designee before unblinding the 
subject, whenever possible  
Treatment assig nment is not to be provided to site personnel, other than the unblinded study 
pharmacist (when applicable), at any time during the conduct of the study, except in the case of a 
true emergency.  In the event that there is no study pharmacist, the individual  at the site fulfilling 
that role will be the only unblinded member of the site personnel.  
7.6. Treatment Logistics and Accountability  
7.6.1.  Packaging, Labeling, and Storage  
Dupilumab/dupilumab placebo: A medication numbering system will be used to label blinded 
dupilumab/dupilumab placebo.  Lists linking medication numbers with product lot numbers will 
be maintained by the groups (or companies) responsible for study drug packaging.  In order to 
maintain the blind, these lists will not be accessible to individuals inv olved in study conduct.  
SCIT and SCIT placebo (SCIT diluent) will display the product lot number on the label.   
Both study drug dupilumab/ dupilumab placebo, and SCIT/SCIT placebo will be stored at the 
site  storage instruct ions will be provided in the pharmacy manual.  
7.6.2.  Supply and Disposition of Treatments  
Study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT) will be shipped 
 to the investigator or designee at regular intervals or as needed 
during the study.  At specified time points during the study (eg, interim site monitoring visits), at 
the site close -out visit, and following drug reconciliation and documentation by the site monitor, 
all opened and unopened study dr ug (dupilumab or placebo for dupilumab and SCIT or placebo 
for SCIT) will be returned to the sponsor.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 48 of 87 
CONFIDENTIAL  7.6.3.  Treatment Accountability  
All drug accountability records must be kept current.  
The investigator must be able to account for all opened and unopened study drug (dupilumab or 
placebo for dupilumab and SCIT or placebo for SCIT).  These records should contain the dates, 
quantity, and study medication:  
 dispensed to each subject,  
 returned from each subject (if applicable), and  
 disposed of at the site or returned  to the sponsor or designee.  
All accountability records must be made available for inspection by the sponsor and regulatory 
agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study.  
7.6.4.  Treatment Compliance  
All study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT) compliance 
records must be kept current and made available for inspection by the sponsor and regulatory 
agency inspectors.  
7.7. Concomitant Medications and Procedures  
Any treatment administered f rom the time of informed consent to the time before the 
administration of study drug (dupilumab or placebo for dupilumab and SCIT or placebo for 
SCIT) will be recorded as pretreatment medication.  Any treatment administered from the first 
dose of study dru g (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT) to the 
end of the follow -up period will be considered concomitant medication.  This includes 
medications that were started before the study and are ongoing during the study.  
The NIMP lorat adine that is given before each SCIT (or placebo for SCIT) dose will also be 
recorded as a concomitant medication.  
7.7.1.  Prohibited Medications (After Randomization) and Procedures  
Prohibited medications are not to be used after randomization except as noted in Section  7.2.  
Treatment with prohibited medications is allowed during the study if medically necessary as 
judged by the investigator (ie, as needed f or allergic symptoms related to SCIT or SCIT placebo 
or related to study procedures).   
Use of leukotriene inhibitors, mast cell inhibitors, corticosteroids including systemic, intranasal, 
or inhaled corticosteroids, oral or topical decongestants, systemic  or topical calcineurin 
inhibitors, beta blockers, long -acting beta agonist (LABA), and long -acting muscarinic 
antagonist (LAMA) will be prohibited for the duration of the study.  
7.7.2.  Permitted Medications and Procedures  
Use of standard of care medications not listed as prohibited will be allowed .  Antihistamines will 
be allowed during the study with the exception of within 5 days of and including the day of 
NAC.   
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 49 of 87 
CONFIDENTIAL  8. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  
8.1. Schedule of Events  
Study assessments and procedures are pr esented by study period and visit in Table  3. 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc . Page 50 of 87 
CONFIDENTIAL  Table  3: Schedule of Events  
Study Procedure  Screening Period   Treatment Period       
V1 V2 NAC  
V3 R1 
V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14  
V15 EOT  
NAC  
V16 V17 Unscheduled 
Visit (if 
applicable)13 EOS  
V18 ET 
Week (W)    1 2 3 4 5 6 7 8 10 13 16 17 20  24  
Study Day  +1 to -84 1 8 15 22 29 36 43 50 57 71 92 113 120 141  169  
Window in Weeks  ±1  -1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1  ±318  
Screening/Baseline                      
Inclusion/Exclusion  X X X X                  
Informed Consent  X                    
 
 
 X                    
Medical History  X                    
Demographics  X                    
Randomization (R)     X                 
SPT for Timothy 
Grass  X                    
Serum Timothy 
Grass sIgE  X                    
Treatment:                      
Dupilumab/  
PBO loading2    
X                 
Dupilumab 300 mg 
q 2 weeks dosing2, 3      X --------------------------- X-------------------------------    X   
Visit for SCIT 
Injections4, 5,     X X5 X X5 X X5 X X X5 X X5   X   
Premedicate with 
loratadine 10 mg 
orally6     X X X X X X X X X X X   X   
Training for Self -
injection 
(dupilumab/PBO)     X                 
Dupilumab/PBO 
distribution     X   X      X  X    X   
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc . Page 51 of 87 
CONFIDENTIAL  Study Procedure  Screening Period   Treatment Period       
V1 V2 NAC  
V3 R1 
V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14  
V15 EOT  
NAC  
V16 V17 Unscheduled 
Visit (if 
applicable)13 EOS  
V18 ET 
Week (W)    1 2 3 4 5 6 7 8 10 13 16 17 20  24  
Study Day  +1 to -84 1 8 15 22 29 36 43 50 57 71 92 113 120 141  169  
Window in Weeks  ±1  -1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1  ±318  
Dupilumab/PBO 
diary review/  
Accountability7      -------------------------------- X----------------------------------    X  X 
Subject Dosing 
Diary8    X   X  X  X  X X X     X  X 
Concomitant Meds  X X X X X X X X X X X X X X X X X X X X 
Efficacy:                      
TNSS  X X           X  X    X 
TOSS    X             X    X 
PNIF    X             X    X 
Intradermal skin 
challenge testing 
(LPR)    X             X    X 
Skin Prick Test 
with Serial 
Allergen Titration  
(EPR)    X             X    X 
Safety:                      
Weight  X  X             X  X  X 
Height  X                    
Vital Signs  X  X X X X X X X X X X X X X X X X X X 
Physical 
Examination  X  X             X  X X X 
Spirometry   X                X   
ECG   X              X  X X X 
Peak expiratory 
flow9  X X             X  X   
Adverse events  X X X X X X X X X X X X X X X X X X X X 
Laboratory 
Testing                      
HIV Ab, HBsAg, 
HBcAb, Hep C Ab,   X                X   
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc . Page 52 of 87 
CONFIDENTIAL  Study Procedure  Screening Period   Treatment Period       
V1 V2 NAC  
V3 R1 
V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14  
V15 EOT  
NAC  
V16 V17 Unscheduled 
Visit (if 
applicable)13 EOS  
V18 ET 
Week (W)    1 2 3 4 5 6 7 8 10 13 16 17 20  24  
Study Day  +1 to -84 1 8 15 22 29 36 43 50 57 71 92 113 120 141  169  
Window in Weeks  ±1  -1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1  ±318  
Hematology, 
Chemistry   X      X    X  X  X X X X X 
Urinalysis   X      X    X  X  X X X X X 
Pregnancy Test if 
indicated [in 
WOCBP]   X14  X15    X15    X15  X15  X15 X15 X15 X14 X14 
Nasal mucosal 
brushing10  X16 X             X17  X    X 
Nasal fluid 
collection     X             X    X 
Future Biomedical 
Research:                      
Research serum11, 12   X X  X  X   X  X  X  X   X X 
Research plasma11, 
12   X X  X  X  X  X  X  X   X X 
 
 
   X                  
Biomarker:                      
Blood for basophil 
sensitivity assays, 
Th2A profiling and 
PBMC banking11 
   X             X    X 
SerumTARC11   X X    X    X  X  X X  X X 
Serum total IgE11   X X  X  X  X  X  X  X X  X X 
Serum Timothy 
Grass sIgE11   X X  X  X  X  X  X  X X  X X 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc . Page 53 of 87 
CONFIDENTIAL  Study Procedure  Screening Period   Treatment Period       
V1 V2 NAC  
V3 R1 
V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14  
V15 EOT  
NAC  
V16 V17 Unscheduled 
Visit (if 
applicable)13 EOS  
V18 ET 
Week (W)    1 2 3 4 5 6 7 8 10 13 16 17 20  24  
Study Day  +1 to -84 1 8 15 22 29 36 43 50 57 71 92 113 120 141  169  
Window in Weeks  ±1  -1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1  ±318  
Serum Timothy 
Grass sIgG411   X X  X  X  X  X  X  X X  X X 
Drug 
Concentration and 
ADA:                      
Functional 
dupilumab PK11, 12   X      X   X  X  X X  X X 
Anti-drug 
antibody11, 12 
(ADA)    X                 X    X X 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 54 of 87 
CONFIDENTIAL  8.1.1.  Footnotes for the Schedule of Events Table  
1. Randomization (V4) must occur within 2 weeks of NAC (V3)  
2. Dupilumab or placebo  for dupilumab loading dose is given day of randomization.  
Subsequent dupilumab/placebo dosing is given Q2W.  
3. Dupilumab/placebo dosing must be given ±3 days of the visit window.  
4. SCIT/placebo should be given 1 to 7 days following dupilumab/placebo loading dose.  
Subsequent SCIT/placebo dosing follows dosing regimen as depicted in Table  1.  
5. During week 2, week 4, week 6, week 10, and week 16, when both dupilumab/placebo 
and SCIT/placebo are given in the same week, SCIT/placebo and dupilumab/placebo are 
NOT to be given on the s ame day (can be 1 day to 7 days apart) AND SCIT/placebo and 
dupilumab/placebo are to be given in a different anatomical location.  
6. For SCIT/placebo visits, subjects are to be premedicated with an antihistamine as 
described in Section  5.1.1.2   
7. Starting at visit 4, study drug will be dispensed to the subject for the dose that will be 
administered before the next dupilumab/placebo distribution visit.  Sub jects will return 
the original kit box at each dupilumab/placebo distribution visit for accountability  
8. For subjects who choose to self -administer study drug, counsel subject on proper dosing 
diary completion/reporting of each dose of study drug that is adm inistered outside of the 
study site  
9. Peak expiratory flow will be measured prior to NAC in any subject with a history of 
asthma.  Peak expiratory flow must be >80% predicted to perform the NAC in any 
subject with a history of asthma (please refer to the pea k flow meter chart in the Study 
Operations Manual as a reference of predicted peak expiratory flow values)  
10. Collected 6 hours post NAC  
11. Collected pre -NAC  
12. Serum samples to be collected for ADA and PK assessments, prior to dosing of 
dupilumab at timepoints ind icated in the Schedule of events  
13. Assessments and procedures at the unscheduled visit are to be performed at the discretion 
of the principal investigator  
14. Serum pregnancy test  
15. Urine pregnancy test  
16. Baseline nasal brushing and nasal brushing on study drug (which is performed at least 28 
days before the final NAC) will not be performed if they interfere with the subject’s 
timely completion of the study (prior to the onset of the subsequent allergy season) as 
outlined in the Study Operations Manual  
17. Should be performed approximately 28 days before the final NAC  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 55 of 87 
CONFIDENTIAL  18. The visit should be conducted as close as possible to the designated study schedule date 
and the window for the days used only as needed.   
8.1.2.  Early Termination Visit  
Subjects who are withdrawn from the stu dy treatment before the primary endpoint visit 
(week  17) will be asked to return to the study site once for an early termination visit consisting of 
the end of treatment assessments described in Table  3, which includes an end of treatment NAC . 
Subjects should return as soon as possible for the end of treatment assessment, so that the NAC 
assessment may be performed while study drug(s) (dupil umab or placebo for dupilumab and 
SCIT or placebo for SCIT) were recently administered.  Subjects who are withdrawn from the 
study treatment after the primary endpoint visit will be asked to return to the study site for early 
termination assessments, inclu ding NAC.  
8.1.3.  Unscheduled Visits  
All attempts should be made to keep subjects on the study schedule.  Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follow -up of AEs, or for 
any other reason, as warranted.  
8.2. Stud y Procedures  
8.2.1.  Efficacy Procedures  
A variety of parameters will be collected during the study to assess efficacy/effectiveness of 
dupilumab monotherapy, SCIT monotherapy, dupilumab + SCIT, and placebo.  
Questionnaires and subject -reported assessments should b e administered prior to obtaining 
investigator assessments, safety and laboratory assessments, and study drug (dupilumab or 
placebo for dupilumab and SCIT or placebo for SCIT) administration.  
Please see Study Operations Manual for detailed instructions on  the procedures and the 
administration and use of all subject -reported instruments.   
8.2.1.1.  NAC and NAC assessments:  TNSS, TOSS, PNIF, and Total Sneezes  
The NAC and NAC assessments will be administered by study site personnel as noted in 
Table  3.  
At the week 17 NAC on study drugs (dupilumab or placebo for dupilumab and SCIT or placebo), 
subjects may not have taken anti -histamines for at least 5 days.  If the subject reports having 
taken anti -histamines within 5 days of the final NAC, they can be rescheduled for the week 17 
visit so long as they have not taken anti -histamines within 5 days of the visit.  
TNSS  
At the end of treatment NAC (week 17), subjects will be observed for approximately 10 minutes 
and a resting/baseline TNSS  ≤2 must be achieved, signifying that the subject does not have 
active nasal symptoms at rest (due to viral infection, sinusitis, allergies, etc.), prior to NAC.  
TNSS (measured on a 0 -12 scale) is a composite symptom assessment of congestion, itching, 
rhinorrhea (each graded on 0 -3 scale, 3 being severe), and sneezing (2 being 3 -4 sneezes and 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 56 of 87 
CONFIDENTIAL  3 being >5 sneezes.  TNSS report will be included in the Study Operations Manual.  If the 
subject has a resting/baseline TNSS≤2 and therefore has no appreciable nasal symptoms at rest, a 
NAC will be performed.  The NAC will be performed using increasing doses of Timothy Grass 
extract every 10 min utes, with TNSS score recorded approximately every 10 min utes (up -
titration symptom score), up until they reach the concentration of Timothy Grass extract that was 
used to achieve a Total Nasal Symptom Score (TNSS) ≥7 at their baseline NAC visit.  This 
TNSS score will be recorded.  After recording the TNSS attai ned using concentration of Timothy 
Grass extract that was used to achieve a Total Nasal Symptom Score (TNSS) ≥7 at their baseline 
NAC visit, the subject will be observed for the subsequent hour and the TNSS will be recorded at 
5 minutes, 15  minutes, 30 min utes, 45 minutes, 1 hour, and then hourly up to 6 hours.  
TOSS  
TOSS (measured on a 0 -3 scale, 3 being severe) is a composite symptom assessment of ocular 
symptoms (Itchy, Red, tearing [eyes watering], and swelling [puffy eyes] (see TOSS report in 
Study Oper ations Manual).  The TOSS score will be recorded during the NAC assessments.  The 
TOSS score will be recorded approximately every 10 minutes (up -titration symptom score), up 
until they reach the concentration of Timothy Grass extract that was used to achie ve a TNSS ≥7 
at their baseline NAC visit.  This TOSS score will be recorded.  The subject will be observed for 
the subsequent hour and the TOSS score will be recorded at 5 minutes, 15 minutes, 30 minutes, 
45 minutes, 1 hour, and then hourly up to and at 6 hours as noted in Table  3. 
PNIF  
Peak nasal inspiratory flow (measured in nasal patency, L/min) will be measured and recorded 
approximately every 10 min utes during the uptitration phase of the NAC and will be measured 
and recorded during the subsequent hour after peak TNSS is achieved (at 5 minutes, 15  minutes, 
30 minutes, 45 minutes, and 1 hour) and hourly up to an at 6 hours as noted in Table  3. 
Total Sneezes  
Total sneezes will be counted and recorded during the uptitration phase and during the hour after 
peak TNSS is achieved.  
8.2.1.2.  Skin Prick Test with Se rial Allergen Titration  
The SPT with serial allergen titration assesses the early phase reaction at 0 -60 minutes.  It will be 
performed as noted in Table  3. 
8.2.1.3.  Intradermal Allergen Injection  
The intradermal allergen injection assesses late phase reaction from 6 -24 hours.  It will be 
performed as noted in Table  3. 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 57 of 87 
CONFIDENTIAL  8.2.1.4.  Nasal Brushing  
Nasal Brushings at Baseline and at Approximately 12 Weeks on Study Drugs.  
The nasal brushing procedure will be performed at baseline, approximately 28 days prior to the 
initial NAC visit.  The baseline nasal brushing must occur while TNSS  ≤2 and it must be at least 
28 days prior to the screening visit 3/Entry visit, so that the nasal mucosa may re -epithelialize 
and return to a resting state prior to NAC.  If the subject reports nasal symptoms and has a 
TNSS2 at Screening visit 2, they can be rescheduled for screening visit 2 when they are no 
longer symptomatic - for re -evaluation  by TNSS.  The baseline nasal brushing should not be 
performed if the 28 day waiting period until the NAC will compromise the subject’s ability to 
complete the 16 week treatment period and final 17 week NAC prior to the subsequent allergy 
season (eg, subje cts cannot have any expected seasonal or environmental allergic symptoms at 
the week 17 NAC visit).  If however, the full 16 week treatment period and 17 week NAC visit is 
expected to be completed prior to the subsequent allergy season, subjects should und ergo 
baseline nasal brushing.  Forgoing the baseline nasal brushing in this case will not be considered 
a protocol deviation, but the event will be recorded and justified.  It is expected that subjects who 
are enrolled in the final month of the enrollment period, as described in the Study Operations 
Manual, will not undergo the baseline nasal brushing.  
Nasal Brushings after NAC:  At Screening Visit 3/Entry Visit Prior to Randomization and 
at Week 17 Visit on Study Drug Must be Performed on All Subjects.  
The required nasal brushings will occur 6 hours after NAC at screening visit 3/Entry visit and 
will occur 6 hours after NAC at the week 17 visit on study drug.   
8.2.1.5.  Nasal Fluid Collection  
Nasal fluid is collected during the 2 NAC study visits to determine the l evels of cytokines and  
chemokines produced in response to NAC.  Nasal fluid is collected (1) at the initial NAC visit: at 
baseline prior to NAC and over the course of 6 hours after NAC and (2) at the 17 week (on study 
drug) NAC visit at baseline prior to NAC and over the course of 6 hours after NAC.   
8.2.2.  Safety Procedures  
8.2.2.1.  Vital Signs  
Vital signs, including temperature, sitting blood pressure, pulse, and respiration will be collected 
predose at time points according to Table  3. 
8.2.2.2.  Physical Examination  
A thorough and complete physical examination will be performed at time points according to 
Table  3.  Care should be taken to examine and assess any abnormalities that may be present, as 
indicated by the subject’s medical history.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 58 of 87 
CONFIDENTIAL  8.2.2.3.  Electrocardiogram  
A standard 12 -lead ECG will be performed at time points according to Table  3.  Heart rate will 
be recorded from the ventricular rate and the PR, QRS, an d QT (identify QTcB or QTcF) 
intervals will be recorded.  The ECG strips or reports will be retained with the source.  
8.2.2.4.  Spirometry  
Spirometry will be performed in all subjects.  If subjects have asthma and use short acting 
medications, the following instruct ions must be followed: after withholding the last dose of 
salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, FEV1, forced vital 
capacity (FVC) and forced expiratory flow at 25% to 75% of forced vital capacity (FEF 25 -75) 
will be dete rmined at screening visit 2.  
8.2.2.5.  Peak Expiratory Flow  
Peak expiratory flow will be measured using a peak flow meter (L/min) in any subject with a 
history of asthma prior to NAC on the day of the NAC.  Peak expiratory flow must be >80% 
predicted to perform the NAC in any subject with a history of asthma.  Detailed instructions for 
peak expiratory flow are included in the Study Operations Manual.  
8.2.2.6.  Laboratory Testing  
Hematology, chemistry, urinalysis, and pregnancy testing samples will be analyzed by a central 
laboratory.  Detailed instructions for blood sample collection are in the laboratory manual 
provided to study sites.  
Samples for laboratory testing will be collected at visits according to Table  3.  Tests will include:  
Blood Chemistry  
Sodium  Total protein, serum  Total bilirubin  
Potassium  Creatinine  Total cholesterol*  
Chloride  Blood urea nitrogen (BUN)  Triglycerides  
Carbon dioxide  Aspartate aminotransferase  (AST)  Uric acid  
Calcium  Alanine aminotransferase (ALT)  Creatine phosphokinase 
(CPK)  
Glucose  Alkaline phosphatase   
Albumin  Lactate dehydrogenase (LDH)   
 
*(low -density lipoprotein [LDL] and high -density lipoprotein [HDL])  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 59 of 87 
CONFIDENTIAL  Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
Urinalysis  
Color  Glucose  RBC  
Clarity  Blood  Hyaline and other casts  
pH Bilirubin  Bacteria  
Specific gravity  Leukocyte esterase  Epithelial cells  
Ketones  Nitrite  Crystals  
Protein  WBC  Yeast  
Other Laboratory Tests  
HIV Ab, HBsAg, HBcAb, and Hep C Ab will be performed at screening visit 2.   
Abnormal Laboratory Values and Laboratory Adverse Events  
All laboratory values must be reviewed by the investigator or authorized designee.  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality.  When necessary,  appropriate ancillary investigations 
should be initiated.  If the abnormality fails to resolve or cannot be explained by events or 
conditions unrelated to the study medication or its administration, the Medical/Study Director 
must be consulted.   
The clin ical significance of an abnormal test value, within the context of the disease under study, 
must be determined by the investigator.  
Criteria for reporting laboratory values as an AE are provided in Section  9.4.5 . 
8.2.3.  Drug Concentration and Measurements  
Samples for drug concentration will be collected at time points listed in Table  3.  
. 
8.2.4.  Anti -Drug Antibody Measurements and Samples  
Samples for ADA assessment will be collected at time points listed in Table  3. 
. 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 60 of 87 
CONFIDENTIAL  8.2.5.  Pharmacodynamic and Biomarker Procedures  
8.2.5.1.  Biomarker Sample collections  
Biomarker sam ples will be collected at time points according to Table  2. Biomarker 
measurements (TARC, total IgE, Timothy Grass specific IgE, Timothy Grass specific IgG4) will 
be performed in serum or plasma to determine effects on biomarkers of relevant physiological 
and pathogenic processes.  
Biomarker results will be used to better understand the pathophysiology of Timothy Grass 
allergy, mechanism of action of dupil umab  and possible toxicities. In addition to the circulating 
biomarkers above, transcriptome sequencing of nasal mucosa after NAC, cytokine/chemokine 
measurements in nasal secretions, basophil allergen sensitivity and Th2A assays will be 
performed.  
 
 
 
 
  
 
 
  
  
 
   
  
 
 
 
 
 
 
   
 
   
  
 
 
  
 
   
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 61 of 87 
CONFIDENTIAL   
 
   
 
 
 
 
 
 
         
 
 
 
  
9. SAFETY  DEFINITIONS, REPORT ING, AND MONITORING  
9.1. Obligations of Investigator  
The investigator must promptly report to the Institutional Review Board (IRB)/Ethics Committee 
(EC) all unanticipated problems involving risks to subjects, according to local regulations.  This 
may include death from any cause and all serious adverse events (SAEs) related to the use of the 
study drug (dupilumab or placebo for dupilumab and SCIT or placebo for SCIT).  It is 
recommended that all SAEs be reported to the IRB/EC, according to lo cal regulations.  
9.2. Obligations of Sponsor  
During the course of the study, the sponsor will report in an expedited manner all SAEs that are 
both unexpected and at least reasonably related to the study drug (dupilumab or placebo for 
dupilumab and SCIT or place bo for SCIT) (suspected unexpected serious adverse reaction 
[SUSAR]), to the health authorities, IECs/IRBs as appropriate, and to the investigators (in a 
blinded manner).  
Any AE not listed as an expected event in the Reference Safety Information section o f the 
Investigator’s Brochure will be considered as unexpected.  Any worsening of or new onset of 
allergy symptoms related to the nasal allergen challenge which occur during the screening period 
prior to study drug (dupilumab or placebo for dupilumab and S CIT or placebo for SCIT) 
administration will be considered expected  (Section  9.4.1 ). 
In addition, the sponsor will report all other SAEs to the health authorities, according to local 
regulations.  
At the completion of the study, the sponsor will report all safety observations made during the 
conduct of the trial in the clinical study report to health authorities and IECs/IRB as appropriate.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00

Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 62 of 87 
CONFIDENTIAL  9.3. Definitions  
9.3.1.  Adverse Event  
An AE is any untoward medical occurrence in a subject administered a study drug which may or 
may not have a causal relationship with the study drug.  Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, o r disease which is 
temporally associated with the use of a study drug, whether or not considered related to the study 
drug.  
An AE also includes any worsening (ie, any clinically significant change in frequency and/or 
intensity) of a pre -existing condition that is temporally associated with the use of the study drug.  
9.3.2.  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  – includes all deaths, even those that appear to be completely 
unrelated to study drug (eg, a c ar accident in which a subject is a passenger).  
 Is life-threatening  – in the view of the investigator, the subject is at immediate risk 
of death at the time of the event.  This does not include an AE that had it occurred in 
a more severe form, might have c aused death.  
 Requires in -patient hospitalization  or prolongation of existing hospitalization .  
In-patient hospitalization is defined as admission to a hospital or an emergency room 
for longer than 24 hours.  Prolongation of existing hospitalization is defi ned as a 
hospital stay that is longer than was originally anticipated for the event, or is 
prolonged due to the development of a new AE as determined by the investigator or 
treating physician.  
 Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).   
 Is a congenital anomaly/birth defect  
 Is an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospitalization, but may jeopardize the subject or 
may require intervention to prevent one of the other serious outcomes listed above 
(eg, intensive treatment in an emergency room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospi talization; or development 
of drug dependency or drug abuse).  
9.4. Recording and Reporting Adverse Events  
9.4.1.  Adverse Events  
The investigator (or designee) will record all AEs that occur from the time the informed consent 
is signed until the end of study, with the exception of symptoms that occur in response to the 
NAC on the day of the NAC.  Allergic symptoms that occur in response to the NAC are not to be 
reported as AEs, as they will be recorded as outcome measures.  However, AEs that occur in 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 63 of 87 
CONFIDENTIAL  response to the NAC  that are outside of expected symptoms which are recorded in response to 
the NAC, or SAEs, should be reported as AEs and SAEs.  Information on follow -up for AEs is 
provided in Section  9.4.6 .  Laboratory, vital signs, or ECG abnormalities are to be recorded as 
AEs as outlined in Section  9.4.5 . 
9.4.2.  Serious Adverse Events  
All SAEs, regardless of assessment of causal relationship to study drugs (dupilumab or placebo 
for dupilumab and SCIT or placebo for SCIT) or procedures, must be reported to the sponsor (or 
designee) within 24 hours.   
Information not av ailable at the time of the initial report must be documented in a follow -up 
report.  Substantiating data such as relevant hospital or medical records and diagnostic test 
reports may also be requested.  
In the event the investigator is informed of an SAE aft er the subject completes the study, the 
following will apply:  
 SAE with an onset within 30 days of the end of study or within 30 days of last study 
drug administration if the subject early terminated from the study - the SAE will be 
reported to the sponsor.   The investigator should make every effort to obtain 
follow -up information on the outcome until the event is considered chronic and/or 
stable.  
 SAE with an onset day greater than 30 days from the end of study/early termination 
visit - only fatal SAEs and t hose deemed by the investigator to be drug -related SAEs 
will be reported to the sponsor.  The investigator should make every effort to obtain 
follow -up information on the outcome of a drug -related SAE until the event is 
considered chronic and/or stable.  
9.4.3.  Other Events that Require Accelerated Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of 
learning of the event:  
Symptomatic Overdose of Study Drug:  Accidental or intentional overdose of at least 
2 times the intended dose of study drugs within the intended therapeutic window, if 
associated with an AE,  
Pregnancy:  Although pregnancy is not considered an AE, it is the responsibility of the 
investigator to report to the sponsor (or designee), within 24  hours of identification, 
any pregnancy occurring in a female study subject during the study or within 
12 weeks of the last dose of study drugs. Any complication of pregnancy affecting a 
female study subject and/or fe tus and/or newborn that meets the SAE criteria must 
be reported as an SAE. Outcome for all pregnancies should be reported to the 
sponsor.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 64 of 87 
CONFIDENTIAL  Adverse Events of Special Interest (AESIs):  All AESI, serious and nonserious, must be 
reported within 24 hours of iden tification using the same reporting process as for 
SAE reporting, per Section  9.4.2 .  Adverse events of special interest for this study 
include the following:  anaphylactic reactions, systemic or severe hypersensitivity 
reactions, malignancy (except in -situ carcinoma of the cervix, non -metastatic 
squamous or basal cell carcinoma of the skin), helminthic infections, suicide -related 
events, any type of conjunctivitis or blepharitis (severe or serious or lasting ≥4 
weeks), keratitis.  
Refer to the study manual for the procedures to be followed.  
9.4.4.  Reporting Adverse Events Leading to Withdrawal from the Study  
All AEs that lead to a subject’s withdrawal from th e study must be reported to the sponsor’s 
Medical/Study Director within 30 days.  
9.4.5.  Abnormal Laboratory, Vital Signs, or Electrocardiogram Results  
The criteria for determining whether an abnormal objective test finding should be reported as an 
AE include:  
 the test result is associated with accompanying symptoms, and/or  
 the test result requires additional diagnostic testing or medical/surgical intervention, 
and/or  
 the test result leads to a change in dosing (outside of protocol -stipulated dose 
adjustments), dis continuation from the study, significant additional concomitant drug 
treatment, or other therapy  
Contact the Medical/Study Director in the event the investigator feels that an abnormal test 
finding should be reported as an AE, although it does not meet any  of the above criteria.  
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an 
AE.  Any abnormal test result that is determined to be an error does not require reporting as an 
AE. 
Evaluation of severity of laborat ory abnormalities will be assessed according to the scale 
outlined in Section  9.5.1 . 
9.4.6.  Follow -up 
Adverse  event information will be collected until th e subject’s last study visit.  
Serious adverse event information will be collected until the event is considered chronic and/or 
stable.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 65 of 87 
CONFIDENTIAL  9.5. Evaluation of Severity and Causality  
9.5.1.  Evaluation of Severity  
The severity of AEs will be graded according to the following  scale:  
 Mild:  Does not interfere in a significant manner with the patient normal functioning 
level.  It may be an annoyance.  Prescription drugs are not ordinarily needed for relief 
of symptoms but  may be given because of personality of the patient.  
 Moderate:   Produces some impairment of functioning but is not hazardous to health.  
It is uncomfortable or an embarrassment.  Treatment for symptom may be needed.  
 Severe:   Produces significant impairment of functioning or incapacitation and is a 
definite h azard to the subject’s health.  Treatment for symptom may be given and/or 
patient hospitalized.  
The severity of AEs related to SCIT or SCIT -placebo for SCIT -related -allergic or anaphylactic 
reactions (including AESIs) will be graded according to the Common  Terminology Criteria for 
Adverse Events (CTCAE), Version 4.3, criteria for grading allergic reactions and anaphylaxis 
(Cox, 2010 ) (Appendix  1).  Not all AEs but only the SCIT or SCIT -placebo -related -allergic or 
anaphylactic reactions (including AESIs) will be graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE).  
If a laboratory value is considered  an AE, its severity should be based on the degree of 
physiological impairment the value indicates.  
Injection Site Reactions  due to study drug (dupilumab or placebo for dupilumab and SCIT or 
placebo for SCIT)   
The severity of injection site reactions will  be graded according to the following scale 
(semi -colon indicates “or” within description of grade):  
 Mild :  Pain that does not interfere with activity; mild discomfort to touch; <5 cm of 
erythema or induration that does not interfere with activity  
 Moderate :  Pain that requires repeated use of non -narcotic pain reliever >24 hours or 
interferes with activity; discomfort with movement; 5.1 cm to 10 cm erythema or 
induration or induration that interferes with activity  
 Severe :  Pain that requires any use of narcotic pain reliever or that prevents daily 
activity; significant discomfort at rest; >10 cm erythema or induration; prevents daily 
activity; requires ER visit or hospitalization; necrosis or exfoliative dermatitis  
9.5.2.  Evaluation of Causality  
Relationship of  Adverse Events to Dupilumab or placebo for dupilumab:  
The relationship of AEs to study drug (dupilumab or placebo for dupilumab) will be assessed by 
the blinded investigator, and will be a clinical decision based on all available information.   The 
followi ng question will be addressed:  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 66 of 87 
CONFIDENTIAL  Is there a reasonable possibility that the AE may have been caused by dupilumab or placebo for 
dupilumab?  
The possible answers are:  
Not Related : There is no reasonable possibility that the event may have been caused by 
the st udy drug (dupilumab or placebo for dupilumab)  
Related : There is a reasonable possibility that the event may have been caused by 
the study drug (dupilumab or placebo for dupilumab)  
The investigator should justify the causality assessment of each SAE.  
A list of factors to consider when assessing the relationship of AEs to dupilumab or placebo for 
dupilumab is provided below.  Please note that this list is not exhaustive.  
Is there a reasonable possibility that the event may have been caused by dupilumab or p lacebo 
for dupilumab?  
No: 
 due to external causes such as environmental factors or other treatment(s) being 
administered  
 due to the subject’s disease state or clinical condition  
 do not follow a reasonable temporal sequence following the time of administrati on of 
the dose of study drug (dupilumab or placebo for dupilumab)  
 do not reappear or worsen when dosing with study drug (dupilumab or placebo for 
dupilumab) is resumed  
Yes: 
 could not be explained by environmental factors or other treatment(s) being 
administered  
 could not be explained by the subject’s disease state or clinical condition  
 follow a reasonable temporal sequence following the time of administration of the 
dose of study drug (dupilumab or placebo for dupilumab)  
 resolve or improve after dis continuation of study drug (dupilumab or placebo for 
dupilumab)  
 reappear or worsen when dosing with study drug (dupilumab or placebo for 
dupilumab)  
 are known or suspected to be a response to the study drug (dupilumab or placebo for 
dupilumab) based upon preclinical data or prior clinical data  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 67 of 87 
CONFIDENTIAL  Relationship of Adverse Events to SCIT or placebo for SCIT:  
The relationship of AEs to SCIT or placebo for SCIT will be assessed by the blinded 
investigator, and will be a clinical decision based on all available inf ormation.  The following 
question will be addressed:  
Is there a reasonable possibility that the AE may have been caused by SCIT or placebo for 
SCIT?  
The possible answers are:  
Not Related:  There is no reasonable possibility that the event may have been caused by 
SCIT or placebo for SCIT  
Related:  There is a reasonable possibility that the event may have been caused by 
SCIT or placebo for SCIT  
The sponsor will request prespecified  information about the SCIT or placebo for SCIT -related 
AEs; instructions  to record this information is in the Study Operations Manual .  
The sponsor will request information to justify the causality assessment of SAEs, as needed.  
A list of factors to consider in assessing the relationship of AEs to SCIT or placebo for SCIT is 
provi ded below. Please note that this list is not exhaustive.  
Is there a reasonable possibility that the event may have been caused by SCIT or placebo for 
SCIT?  
No: 
 due to patient’s disease state or clinical condition  
 do not follow a reasonable temporal sequenc e following SCIT or placebo for SCIT  
 do not reappear or worsen when SCIT or placebo for SCIT is resumed  
 are not a suspected response to SCIT or placebo for SCIT based upon preclinical data 
or prior clinical data  
Yes: 
 could not be explained by environmental  factors or other treatment(s) being 
administered  
 could not be explained by patient’s disease state or clinical condition  
 follow a reasonable temporal sequence following SCIT or placebo for SCIT  
 resolve or improve after discontinuation of SCIT or placebo for SCIT  
 reappear or worsen when SCIT or placebo for SCIT treatment is resumed  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 68 of 87 
CONFIDENTIAL  Relationship of Adverse Events to Study Procedures  
The relationship of AEs to study procedures will be assessed by the blinded investigator, and will 
be a clinical decision base d on all available information.  The following question will be 
addressed:  
Is there a reasonable possibility that the AE may have been caused by the study procedure?  
The possible answers are:  
Not Related:  There is no reasonable possibility that the event m ay have been caused by 
the study procedure.  
Related:  There is a reasonable possibility that the event may have been caused by the study 
procedure.  
The sponsor will request information to justify the causality assessment of SAEs, as needed.  
A list of factors to consider in assessing the relationship of AEs to study procedures is provided 
below.  Please note that t his list is not exhaustive.  
Is there a reasonable possibility that the event may have been caused by study procedures?  
No: 
 due to t he subject’s disease state or clinical condition  
 do not follow a reasonable temporal sequence following study procedure.  
 do not reappear or worsen when the study procedure is resumed  
 are not a suspected response to the study procedure based upon preclinica l data or 
prior clinical data  
Yes: 
 could not be explained by environmental factors or other treatment(s) being 
administered  
 could not be explained by the subject’s disease state or clinical condition  
 follow a reasonable temporal sequence following the stud y procedure.  
 resolve or improve after discontinuation of study drug study procedure.  
 reappear or worsen when the study procedure is resumed  
 are known or suspected to be a response to study procedure based upon preclinical 
data or prior clinical data  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 69 of 87 
CONFIDENTIAL  9.6. Safety  Monitoring  
The investigator will monitor the safety of study subject at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP).  Any questions or 
concerns should be discussed with the sponsor in a  timely fashion.  The sponsor will monitor the 
safety data from across all study sites.  The Medical/Study Director will have primary 
responsibility for the emerging safety profile of the compound, but will be supported by other 
departments (eg, Pharmacovi gilance and Risk Management; Biostatistics and Data 
Management).  Safety monitoring will be performed on an ongoing basis (eg, individual review 
of SAEs) and on a periodic cumulative aggregate basis.  
9.7. Investigator Alert Notification  
Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as 
in any other clinical trial using the same investigational drug, of any SAE that meets the relevant 
requirements for expedited reporting (an AE that is serious, unexpected based  on the reference 
safety information in the Investigator’s Brochure, and has a reasonable suspected causal 
relationship to the study drug).  
10. STATISTICAL PLAN  
This section provides the basis for the statistical analysis plan (SAP) for the study.  The SAP 
may be revised during the study to accommodate amendments to the clinical study protocol and 
to make changes to adapt to unexpected issues in study execution and data that may affect the 
planned analyses.  The final SAP will be issued before the database is l ocked.  
Analysis variables are listed in Section  4. 
10.1. Statistical Hypothesis  
The primary efficacy endpoint is the percent change from baseline in TNSS AUC (0 -1 hr) at 
week  17.  The comparison between dupilumab + SCIT as compared to placebo +  SCIT 
monotherapy will be made.  
Let μD (and μP) be the true mean percent change from baseline in in TNSS AUC (0 -1 hr) for 
Dupilumab + SCIT and Placebo + SCIT, respect ively.  The following hypothesis for the 
superiority testing will be tested at the 5% 2 sided significance level:  
H0: μD = μP, ie, the mean percent change from baseline to week 17 is the same between 
Dupilumab + SCIT and Placebo + SCIT  
against the alterna tive 
Ha: μD ≠ μP, ie, the mean percent changes from baseline to week 17 are different between 
Dupilumab + SCIT and Placebo + SCIT  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 70 of 87 
CONFIDENTIAL  10.2. Justification of Sample Size  
It is estimated that with 25 subjects per group, the study will have 80% power to detect a 
differ ence of 29% between dupilumab plus SCIT and placebo plus SCIT monotherapy with 
respect to percent change from baseline in TNSS AUC (0 -1 hr) at week 17, assuming that the 
mean percent changes from baseline values are -55% and -26% and a common standard 
deviation (SD) of 35% for dupilumab plus SCIT and placebo SCIT monotherapy, respectively. 
The significance level is set to 2 -sided, 0.05 level.  
The assumptions used for primary endpoint were based on the study result from the Scadding 
(2017) study.  The Scaddi ng study shows after 1  year treatment, the difference between SCIT 
and placebo is 34% for the percent change in TNSS AUC (0 -1 hr) at 1 year.  A similar 
magnitude of improvement by adding dupilumab onto SCIT is assumed for the sample size 
calculation.   
10.3. Analysis Sets  
10.3.1.  Efficacy Analysis Sets  
The full analysis set (FAS) includes all randomized subjects.  Efficacy analyses will be based on 
the treatment allocated at randomization (as randomized).  
The per protocol set (PPS) includes all subjects in the FAS except  for those who are excluded 
because of major protocol violations.  A major protocol violation is one that may affect the 
interpretation of study results.  
All efficacy variables will be evaluated on the FAS; the primary endpoint will also be evaluated 
on th e PPS. Analysis on the FAS will be considered to be primary.  
10.3.2.  Safety Analysis Set  
The safety analysis set (SAF) includes all randomized subjects who received any study drug; it is 
based on the treatment received (as treated).  Treatment compliance/administr ation and all 
clinical safety variables will be analyzed using the SAF.  
10.3.3.  Pharmacokinetic Analysis Sets  
The pharmacokinetic (PK) analysis set includes all randomized subjects who received any study 
drug and who had at least 1 non -missing drug concentration r esult following the first dose of 
study drug.  
10.3.4.  Anti -Drug Antibody Analysis Sets  
The ADA population includes all treated subjects who had received any amount of dupilumab 
study drug or dupilumab placebo and had at least 1 non -missing anti -drug antibody resul t 
following the first dose of dupilumab study drug or dupilumab placebo.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 71 of 87 
CONFIDENTIAL  10.4. Statistical Methods  
For continuous variables, descriptive statistics will include the following information:  the 
number of subjects reflected in the calculation (n), mean, median, first quartile (Q1), third 
quartile (Q3), SD, minimum, and maximum.  
For categorical or ordinal data, frequencies and percentages will be displayed for each category.  
10.4.1.  Subject Disposition  
The following will be provided:  
 The total number of screened subjects:   met the inclusion criteria regarding the target 
indication and signed the ICF  
 The total number of randomized subjects:  received a randomization number  
 The total number of subjects in each analysis set (eg, FAS, provided in 
Section  10.3.2 ) 
 The total number of subjects who discontinued the study, and the reasons for 
discontinuation  
 A listing of subjects treated but not randomized, subjects randomized  but not treated, 
and subjects randomized but not treated as randomized  
 A listing of subjects prematurely discontinued from treatment, along with reasons for 
discontinuation  
10.4.2.  Demography and Baseline Characteristics  
Demographic and baseline characteristics w ill be summarized descriptively by treatment group, 
and by all subjects combined.   
10.4.3.  Efficacy Analyses  
10.4.3.1.  Primary Efficacy Analysis  
The primary endpoint will be analyzed by using the multiple imputation (MI) with analysis of 
covariance (ANCOVA) model.  Missing  data will be imputed 40 times to generate 40 complete 
data sets by using the Statistical Analysis System (SAS) procedure MI. Each of the 40 complete 
datasets will be analyzed using an ANCOVA model with treatment group being the main factor 
and baseline va lue as the covariate. The SAS MIANALYZE procedure will then be used to 
generate valid statistical inferences by combining results from the 40 analyses using Rubin’s 
formula.  
All observed data will be used for analysis. Sensitivity analysis such as ANCOVA m odel with 
last observation carry forward (LOCF) method will also be conducted. Additional details on 
sensitivity analyses will be provided in the SAP.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 72 of 87 
CONFIDENTIAL  10.4.3.2.  Secondary Efficacy Analysis  
The continuous secondary efficacy endpoints will be analyzed using the same a pproach as that 
used for the analysis of the primary endpoint.  
The biomarker related continuous endpoint will be analyzed using a rank based ANCOVA 
model with treatment and relevant baseline as covariates. LOCF method will be used to impute 
the missing dat a. 
10.4.3.3.  Multiplicity Considerations  
There is no control for multiplicity on the secondary and exploratory endpoints.  
10.4.3.4.  First -Step Analysis  
A first -step analysis may be performed when the last subject completes 16 weeks of the 
treatment period and performed the NA C at week 17 as specified in the protocol (Visit 16 visit or 
earlier for those subjects who are withdrawn prematurely from the study).  No changes in the 
conduct of the study will be made based on this first -step analysis.  The assessment of primary 
and se condary endpoints up to end of treatment NAC Visit 16 (week 17) as specified in 
Section  4.2.1 and Section 4.2.2  and performed during the analysis will be the final analysis of the 
primary endpoints and secondary endpoints. If a decision is made to perform the first -step 
analysis, in order to maintain study integrity with respect to the post -treatment follow -up visi ts, 
safety visits and analyses, a dissemination plan will be written.  This plan will clearly identify the 
team (including the statistician) that will perform the first -step analysis and all related activities, 
restrict other clinical team members and othe r Sponsor personnel from access to individual 
subject treatment allocation and site level analysis results, and ensure that the dedicated team 
will not participate in the data review or data decisions for the following post treatment analyses.  
However, th e dedicated team can participate in the analysis following the final database lock.  
10.4.4.  Safety Analysis  
10.4.4.1.  Adverse Events  
Definitions  
For safety variables, 2 observation periods are defined:  
 The pretreatment period is defined as the time from signing the ICF to before the first 
dose of study drug.  
 The treatment period is defined as the day from first dose of study drug to end of 
study. The treatment -emergent period includes the 16 -week treatment period and 
follow -up period  
Treatment -emergent adverse events are de fined as those that are not present at baseline or 
represent the exacerbation of a pre -existing condition during the treatment emergent period.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 73 of 87 
CONFIDENTIAL  Analysis  
All AEs reported in this study will be coded using the currently available version of the Medical 
Dicti onary for Regulatory Activities (MedDRA®).  Coding will be to lowest level terms.  The 
verbatim text, the preferred term (PT), and the primary system organ class (SOC) will be listed.  
Summaries of all TEAEs by treatment group will include:  
 The number (n) a nd percentage (%) of subjects with at least 1 TEAE by SOC and PT  
 TEAEs by severity (according to the grading scale outlined in Section  9.5.1  present ed 
by SOC and PT  
 TEAEs by relationship to treatment (related, not related), presented by SOC and PT  
 Treatment -emergent AESIs (defined with a PT or a prespecified grouping)  
Deaths and other SAEs will be listed and summarized by treatment group.  
Treatment -emergent adverse events leading to permanent treatment discontinuation will be listed 
and summarized by treatment group.  
10.4.4.2.  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respiration rate) will be summarized by 
baseline and change  from baseline to each scheduled assessment time with descriptive statistics.  
Laboratory Tests  
Laboratory test results will be summarized by baseline and change from baseline to each 
scheduled assessment time with descriptive statistics.  
Number and percent age of subjects with a potentially clinically significant value (PCSV) at any 
postrandomization time point will be summarized for each clinical laboratory test.  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods may be 
used to present the results for laboratory tests of interest.  
Listings will be provided with flags indicating the out of laboratory range values.  
10.4.4.3.  Treatment Exposure  
The duration of exposure during the study will be presented by treatment group and calculated 
as: 
(Date of last study drug injection – date of first study drug injection) + 14 days  
The number (%) of subjects randomized and exposed to double -blind study drug will be 
presented by specific time periods for each treatment group.  The time pe riods of interest will be 
specified in the SAP.  
In addition, duration of exposure during the study will be summarized for each treatment group 
using number of subjects, means, SD, minimums, Q1, medians, Q3, and maximums.  
A summary of the number of doses by  treatment group will be provided.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 74 of 87 
CONFIDENTIAL  10.4.4.4.  Treatment Compliance  
The compliance with study treatment will be calculated as follows:  
Treatment Compliance of study drug = (Number of study drug injections during exposure 
period)/ (Number of planned study drug injections during exposure period) × 100%  
The treatment compliance will be presented by specific ranges for each treatment group.  The 
ranges of interest will be specified in the SAP.  
10.4.5.  Pharmacokinetics  
Descriptive statistics will be used to summarize the co ncentration data at each sampling time.  
No formal statistical analysis will be performed.  
10.4.6.  Analysis of Anti -Drug Antibody Data  
Listings of treatment -emergent ADA and titers presented by subject, time point, and dose cohort 
will be provided.  Incidence of treatment -emergent and treatment -boosted ADA will be assessed 
as absolute occurrence (N) and percent of subjects (%), grouped by study cohorts and ADA titer 
level.  
Assessment of association of treatment -emergent and treatment boosted ADA with potential 
impact of ADA response on PK, safety and efficacy may be evaluated.  
10.4.7.  Analysis of Pharmacodynamic and Exploratory Biomarker Data  
The exploratory biomarker data will be summarized by descriptive statistics.  
10.5. Additional Statistical Data Handling Conventions  
The following analysis and data conventions will be followed:  
Definition of baseline:  
 The baseline assessment will be the latest, valid pre -first-dose assessment available  
General rules for handling missing data:  
 Rules for handling missing data for assessmen t (other than efficacy)  
 If the start date of an AE or concomitant medication is incomplete or missing, it will 
be assumed to have occurred on or after the intake of study medication, except if an 
incomplete date (eg, month and year) clearly indicates that the event started prior to 
treatment.  If the partial date indicates the same month or year of the intake of study 
medication date, then the start date by the study medication intake date will be 
imputed; otherwise, the missing day or month by the first da y or the first month will 
be imputed.  
 No imputations for missing laboratory data, ECG data, vital sign data, or physical 
examination data will be made.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 75 of 87 
CONFIDENTIAL  Visit windows:  
 Assessments taken outside of protocol allowable windows will be displayed 
according to t he case report form (CRF) assessment recorded by the investigator.  
Unscheduled assessments:  
 Extra assessments (laboratory data or vital signs associated with nonprotocol clinical 
visits or obtained in the course of investigating or managing AEs) will be in cluded in 
listings, but not summaries.  If more than 1 laboratory value is available for a given 
visit, the first observation will be used in summaries and all observations will be 
presented in listings.  
10.6. Statistical Considerations Surrounding the Premature  Termination of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section  16.1. 
11. DATA MANAGEMENT AND ELECTRONIC SYSTEMS  
11.1. Data Management  
A data management plan specifying all relevant aspects of data processing for the study 
(including data validation, cleaning, correcting, releasing) will be maintained and stored at 
Regeneron.  
A medical coding plan will specify the processes and the dictionary used for coding.  All data 
coding  (eg, AEs, baseline findings, medication, medical history/surgical history) will be done 
using internationally recognized and accepted dictionaries.  
The CRF data for this study will be collected with both paper and an electronic data capture 
(EDC) tool.  
11.2. Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
 IVRS/IWRS system – randomization, study drug supply  
 EDC system – data capture  
 Statistical Analysis System (SAS) – statistical revi ew and analysis  
 Pharmacovigilance safety database  
 AWARE, Business Objects XI – pharmacovigilance activities (Sanofi)  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 76 of 87 
CONFIDENTIAL  12. STUDY MONITORING  
12.1. Monitoring of Study Sites  
The study monitor and/or designee (eg, contract research organization [CRO] monitor) will visit 
each site prior to enrollment of the first subject, and periodically during the study.   
The investigator must allow study -related monitoring.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by authorized site personnel are accurate, complete, and verifiable from source documents, 
that the safety and rights of subjects are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agre ements, ICH 
GCP, and all applicable regulatory requirements  
12.2. Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate subject records (source 
documents).  
The investigator must keep all source documents on file wi th the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an electronic CRF).  Case report forms and source 
documents must be available at all times for inspection by authorized representatives of the 
sponsor and regulatory authorities.  
12.3. Case Report Form Requirements  
Study data obtained in the course of the clinical study will be recorded on electronic Case Report 
Forms (CRFs) within the EDC system by trained site personnel.  All required CRFs must be 
completed for each and every subject enro lled in the study.  After review of the clinical data for 
each subject, the investigator must provide an electronic signature.  A copy of each subject  CRF 
casebook is to be retained by the investigator as part of the study record and must be available at 
all times for inspection by authorized representatives of the sponsor and regulatory authorities.  
Corrections to the CRF  will be entered in the CRF by the investigator or an authorized designee.  
All changes, including date and person performing corrections , will be available via the audit 
trail, which is part of the EDC system.  For corrections made via data queries, a reason for any 
alteration must be provided.  
13. AUDITS AND INSPECTIO NS 
This study may be subject to a quality assurance audit or inspection by t he sponsor or regulatory 
authorities.  Should this occur, the investigator is responsible for:  
 Informing the sponsor of a planned inspection by the authorities as soon as 
notification is received, and authorizing the sponsor’s participation in the inspecti on 
 Providing access to all necessary facilities, study data, and documents for the 
inspection or audit  
 Communicating any information arising from inspection by the regulatory authorities 
to the sponsor immediately  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 77 of 87 
CONFIDENTIAL   Taking all appropriate measures requested by the sponsor to resolve the problems 
found during the audit or inspection  
Documents subject to audit or inspection include but are not limited to all source documents, 
CRFs, medical records, correspondence, ICFs, IRB/EC files, documentation of certificat ion and 
quality control of supporting laboratories, and records relevant to the study maintained in any 
supporting pharmacy facilities.  Conditions of study material storage are also subject to 
inspection.  In addition, representatives of the sponsor may o bserve the conduct of any aspect of 
the clinical study or its supporting activities both within and outside of the investigator's 
institution.  
In all instances, the confidentiality of the data must be respected.  
14. ETHICAL AND REGULATO RY CONSIDERATIONS  
14.1. Good C linical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable 
regulatory requirements.  
Informed Consent  
The principles of informed consent are described in ICH guidelines for GCP.  
The ICF used by the investigator must be reviewed and approved by the sponso r prior to 
submission to the appropriate IRB/EC.  A copy of the IRB/EC -approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee  (if acceptable by local regulations) to obtain 
written informed consent from each subject prior to his/her participation in the study and after 
the aims, methods, objectives, and potential hazards of the study have been explained to the 
subject in languag e that he/she can understand.  The ICF should be signed and dated by the 
subject and by the investigator or authorized designee who reviewed the ICF with the subject.   
 Subjects who can write but cannot read will have the ICF read to them before signing 
and dating the ICF.  
 Subjects who can understand but who can neither write nor read will have the ICF 
read to them in presence of an impartial witness, who will sign and date the ICF to 
confirm that informed consent was given.  
The original ICF must be retaine d by the investigator as part of the subject's study record, and a 
copy of the signed ICF must be given to the subject.  
If new safety information results in significant changes in the risk/benefit assessment, the ICF 
must be reviewed and updated appropriat ely.  All study subjects must be informed of the new 
information and provide their written consent if they wish to continue in the study.  The original 
signed revised ICF must be maintained in the subject’s study record and a copy must be given to 
the subj ect. 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 78 of 87 
CONFIDENTIAL  14.2. Subjects Confidentiality and Data Protection  
The investigator must take all appropriate measures to ensure that the anonymity of each study 
subject will be maintained.  Subjects should be identified by a subject identification number 
only, on CRFs or other documents submitted to the sponsor.  Documents that will not be 
submitted to the sponsor (eg, signed ICF) must be kept in strict confidence.  
The subject's and investigator's personal data, which may be included in the sponsor database, 
will be treate d in compliance with all applicable laws and regulations.  The sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by any unauthorized third 
party.  
14.3. Institutional Review Board/Ethics Committee  
An appropriately constitute d IRB/EC, as described in ICH guidelines for GCP, must review and 
approve:  
 The protocol, ICF, and any other materials to be provided to the subjects 
(eg, advertising) before any subject may be enrolled in the study  
 Any amendment or modification to the stud y protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the subject, in 
which case the IRB/EC should be informed as soon as possible  
 Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of subjects or 
the continued conduct of the clinical study.  
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their 
functio ns must be received by the sponsor prior to shipment of drug supplies to the investigator.  
The approval letter should include the study number and title, the documents reviewed, and the 
date of the review.  
Records of the IRB/EC review and approval of all study documents (including approval of 
ongoing studies) must be kept on file by the investigator.  
15. PROTOCOL AMENDMENTS  
The sponsor may not implement a change in the design of the protocol or ICF without an 
IRB/EC -approved amendment  
16. PREMATURE TERMINATIO N OF THE STUDY OR CLOSE -OUT OF A 
SITE  
16.1. Premature Termination of the Study  
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor decide to terminate the study, the 
inves tigator(s) will be notified in writing.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 79 of 87 
CONFIDENTIAL  16.2. Close -out of a Site  
The sponsor and the investigator have the right to close -out a site prematurely.  
Investigator’s Decision  
The investigator must notify the sponsor of a desire to close -out a site in writing, provid ing at 
least 30 days’ notice.  The final decision should be made through mutual agreement with the 
sponsor.  Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The sponsor will notify the investigator(s) of  a decision to close -out a study site in writing.  
Reasons may include the following, among others:  
 The investigator has received all items and information necessary to perform the 
study, but has not enrolled any subject within a reasonable period of time  
 The investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelin es  
 The total number of subjects required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be give n to the protection 
of the subjects’ interests.  
17. STUDY DOCUMENTATION  
17.1. Certification of Accuracy of Data  
A declaration assuring the accuracy and content of the data recorded on the eCRF must be signed 
electronically by the investigator.  This signed declarati on accompanies each set of subject  final 
eCRFs that will be provided to the sponsor.  
17.2. Retention of Records  
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copies of CRFs, and drug accountability records for at least 15  years following the 
completion or discontinuation of the study, or longer, if a longer period is required by relevant 
regulatory authorities.  The investigator must obtain written approval from the sponsor before 
discarding or destr oying any essential study documents during the retention period following 
study completion or discontinuation.  Records must be destroyed in a manner that ensures 
confidentiality.  
If the investigator's personal situation is such that archiving can no longe r be ensured, the 
investigator must inform the sponsor (written notification) and the relevant records will be 
transferred to a mutually agreed -upon destination.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 80 of 87 
CONFIDENTIAL  18. DATA QUALITY ASSURAN CE 
In accordance with ICH E6, the sponsor is responsible for quality assu rance to ensure that the 
study is conducted and the data generated, recorded, and reported in compliance with the 
protocol, GCP, and any applicable regulatory requirement(s).  The planned quality assurance and 
quality control procedures for the study are s ummarized.  
Data Management  
The sponsor is responsible for the data management of this study including quality checking of 
the data (Section  11.1). 
Study Monitoring  
The investigator must allow study -related monitoring, IRB/EC review, audits, and inspections 
from relevant health regulatory authorities, and provide direct access to source data documents 
(Section  12.1, Section  12.2, Section  13)   
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by authorized site personnel are accurate, complete, and verifiable from source documents, 
that t he safety and rights of subjects are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH 
GCP, and all applicable regulatory requirements (Section  12.1).   
All subject/patient data collected during the study will be recorded on paper or electronic CRF 
unless the data are transmitted to the spon sor or designee electronically (eg, laboratory data). The 
investigator is responsible for affirming that data entries in the CRF are accurate and correct by 
electronically signing a declaration that accompanies each set of subject final CRF (Section  12.3 
and Section  17.1).  
Study Documentation  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF (Section  12.2).  
The investigat or will retain all records and documents, including signed ICFs, pertaining to the 
conduct of this study for at least 15 years after study completion, unless local regulations or 
institutional policies require a longer retention period.  No records may be destroyed during the 
retention period without the written approval of the sponsor. No records may be transferred to 
another location or party without written notification to the sponsor (Section  17.2).  
19. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
20. FINANCING AND INSURA NCE  
Financing and insurance information is provided as a separate agreement.  
21. PUBLICATION POLICY  
The publication policy is provided as a separate agreement.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 81 of 87 
CONFIDENTIAL  22. REFERENCES  
Akdis CA, et al. Mechanisms of allergen -specific immunotherapy. J Allergy Clin Immunol. 
2011. 127(1):18 -27. 
Aasbjerg K, et al. Immunological comparisons of allergen immunotherapy tablet  treatment and 
subcutaneous immunotherapy against grass allergy. Clinical & Experimental Allergy. 2014. (44): 
417-428. 
Bachert C, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With 
Chronic Sinusitis and Nasal Polyposis: A Random ized Clinical Trial. JAMA, 2016. 315(5): p. 
469-79. 
Beck LA, et al. Dupilumab treatment in adults with moderate -to-severe atopic dermatitis. N Engl 
J Med, 2014. 371(2): p. 130 -9. 
Bensch GW, et al. Evaluation of cytokines in nasal secretions after nasal ant igen challenge: lack 
of influence of antihistamines. Ann Allergy Asthma Immunol. 2002 88(5):457 -62. 
Burnett M, et al. Relationship of dog - and cat -specific IgE and IgG4 levels to allergic symptoms 
on pet exposure. J Allergy Clin Immunol Pract. 2013. 1(4): p. 350 -3. 
Canonica GW, et al. Sublingual immunotherapy: World Allergy Organization position paper 
2013 update. World Allergy Organ J. 2014. 7(1): p. 6.  
Chaker AM, et al. An accelerated dose escalation with a grass pollen allergoid is safe and 
well-tolerate d: a randomized open label phase II trial. Clin Transl Allergy. 2015a. 6:4.  
Chaker AM, et al. Short -term subcutaneous grass pollen immunotherapy under the umbrella of 
anti-IL-4: A randomized controlled trial. J Allergy Clin Immunol. 2015b. 137:452 -461 e459 . 
Cox L et al. SPEAKING THE SAME LANGUAGE: THE WORLD ALLERGY 
ORGANIZATION SUBCUTANEOUS IMMUNOTHERAPY SYSTEMIC REACTION 
GRADING SYSTEM. J Allergy Clin Immunol. 2010. 125:569 -574, e567.  
Cox L, et al. Allergen Immunotherapy: A Practice Parameter Third Update.  J Allergy Clin 
Immunol. 2011 Jan;127(1 Suppl):S1 -55. doi: 10.1016.  
Creticos PS. Immunotherapy with allergens. JAMA, 1992. 268(20): p. 2834 -9. 
Du Toit G, et al. Identifying infants at high risk of peanut allergy: the Learning Early About 
Peanut Allergy (LE AP) screening study. J Allergy Clin Immunol, 2013. 131(1): p. 135 -43 e1 -12. 
Durham SR, et al. Long -term clinical efficacy of grass -pollen immunotherapy. N Engl J Med, 
1999. 341(7): p. 468 -75. 
Durham SR, et al. SQ -standardized sublingual grass immunotherapy : confirmation of disease 
modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol, 
2012. 129(3): p. 717 -725.e5.  
Durham SR, et al. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy 
Clin Immunol, 2016. 137(2): p. 339 -349.e10.  
Eckman JA, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal 
cat allergen challenge. J Allergy Clin Immunol, 2010. 125(4): p. 889 -895 e7.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 82 of 87 
CONFIDENTIAL  Erin EM, et al. Single dose topical corticosteroid in hibits IL -5 and IL -13 in nasal lavage 
following grass pollen challenge. Allergy. 2005a. 60:1524 -1529.  
Erin, EM, et al. Topical corticosteroid inhibits interleukin -4, -5 and -13 in nasal secretions 
following allergen challenge. Clin Exp Allergy 2005b. 35:16 08-1614.  
Ewbank PA. A double -blind, placebo -controlled immunotherapy dose -response study with 
standardized cat extract. J Allergy Clin Immunol. 2003;111(1):155.  
Feng S, et al. Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic 
rhinitis: a systematic review and meta -analysis. PLoS One. 2014. 9(1): p. e86529.  
Flicker S, et al. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy 
Immunol. 2003. 132(1): p. 13 -24. 
Frew A.J. Allergen immunotherapy.  J Allergy Clin Immunol. 2010. 125(2 Suppl 2): p. S306 -13. 
Frew AJ. Immunotherapy: how safe is safe? Clin Exp Allergy. 2006a. 36(3): p. 251 -3. 
Frew AJ, et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in 
treatment -resistant sea sonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006b. 117(2): 
p. 319 -25. 
Geroldinger -Simic M, et al. Birch pollen -related food allergy: clinical aspects and the role of 
allergen -specific IgE and IgG4 antibodies. J Allergy Clin Immunol. 2011. 1 27(3): p. 616 -22.e1.  
Gokmen NM, et al. Desensitization effect of preseasonal seven -injection allergoid 
immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen -specific 
preseasonal allergoid immunotherapy on basophils. Int Arch Allergy Immunol. 2012. 
159:75 - 82. 
Hamilton, J.D, et al. Dupilumab improves the molecular signature in skin of patients with 
moderate -to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology, 2014. 134(6): 
p. 1293 -1300.  
James, L.K., et al. A llergen specificity of IgG(4) -expressing B cells in patients with grass pollen 
allergy undergoing immunotherapy. J Allergy Clin Immunol . 2012. 130:663 -670 e663.  
Klimek L, et al. Short -term pre -seasonal birch pollen allergoid immunotherapy influences 
sympto ms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral 
T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy 29. 1999a. (10) 1326.  
Klimek, L, et al. Norm values for eosinophil cationic protein in nasa l secretions: influence of 
specimen collection. Clin. Exp. Allergy. 1999b. 29 (3), 367.  
Lalek N, et al. Immunoglobulin G -dependent changes in basophil allergen threshold sensitivity 
during birch pollen immunotherapy. Clin Exp Allergy. 2010; 40: 1186 –93. 
Larche M, et al. Immunological mechanisms of allergen -specific immunotherapy. Nat Rev 
Immunol, 2006. 6(10): p. 761 -71. 
Leaker BR. The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation 
(IL-5 and IL -13), the inflammasome (IL -1beta), and complement. Mucosal Immunol. 2017. 
10:408 -420. 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 83 of 87 
CONFIDENTIAL  Leung DYM, et al. Pediatric allergy: principles and practice. 2nd edition, Elsevier; 2010.  
Lundgren M, et al. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur J 
Immunol, 1989. 19(7):1311 -5. 
Meltzer EO, et al. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency 
for Healthcare Research and Quality or Anchor -Based Thresholds? J Allergy Clin Immunol 
Pract, 2016. 4(4): p. 682 -688.e6.  
Linden M, et al. Immediate  effect of topical budesonide on allergen challenge -induced nasal 
mucosal fluid levels of granulocyte -macrophage colony -stimulating factor and interleukin -5. Am 
J Respir Crit Care Med. 2000 162:1705 -1708.  
Lü FX, et al. Novel nasal secretion collection meth od for the analysis of allergen specific 
antibodies and inflammatory biomarkers. J. Immunol. Methods. 2010. 30 (1 –2), 6 (356).  
Nicholson GC, et al. The effects of an anti -IL-13 mAb on cytokine levels and nasal symptoms 
following nasal allergen challenge. J  Allergy Clin Immunol. 2011. 128:800 -807 e809.  
Nielsen L, et al. Antihistamine Premedication In Specific Cluster Immunotherapy: A 
Double -Blind, Placebo -Controlled Study. J Allergy Clin Immunol. 1996;97(6):1207.  
Nopp A, et al. CD -sens: a biological measure  of immunological changes stimulated by ASIT. 
Allergy. 2009. 64:811 –4. 
Paterniti, M, et al. Cat allergen -induced blood basophil reactivity in vitro predicts acute human 
nasal allergen challenge responses in vivo. Clin Exp Allergy, 2011. 41(7): p. 963 -9. 
Pawankar R, et al. WAO White Book on Allergy 2011, World Allergy Organization.  
Poole A, et al. Dissecting childhood asthma with nasal transcriptomics distinguishes 
subphenotypes of disease. J Allergy Clin Immunol. 2014. 133:670 -678 e612.  
Renand A, et al, Syn chronous Immune Alterations Mirror Clinical Response During Allergen 
Immunotherapy. 2017 J Allergy Clin Immunol, 2017, In press  
Riechelmann H, et al. Biological markers in nasal secretions. Eur. Respir. J. 2003. 21 (4), 600.  
Salo PM, et al. Prevalence of allergic sensitization in the United States: results from the National 
Health and Nutrition Examination Survey (NHANES) 2005 -2006. J Allergy Clin Immunol, 
2014. 134(2): p. 350 -9. 
Scadding GW, et al. Optimisation of grass pollen nasal allergen challenge for  assessment of 
clinical and immunological outcomes. J Immunol Methods. 2012. 384:25 -32. 
Scadding GW, et al., Local and systemic effects of cat allergen nasal provocation. Clin Exp 
Allergy, 2015a. 45(3): p. 613 -23. 
Scadding GW, et al. Effect of grass pollen  immunotherapy on clinical and local immune 
response to nasal allergen challenge. Allergy. 2015b. 70:689 -696. 
Scadding et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on 
Nasal Response to Allergen Challenge at 3 Years Among  Patients With Moderate to Severe 
Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA. 
2017;317(6):615 -625. doi: 10.1001/jama.2016.21040.  
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 84 of 87 
CONFIDENTIAL  Shamji MH, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with 
clinic al response to grass pollen immunotherapy. Allergy, 2012. 67(2): p. 217 -26. 
Spiegelberg, HL, et al.  Interleukin -4 induced IgE and IgG4 secretion by B cells from atopic 
dermatitis patients. Int Arch Allergy Appl Immunol  1991.  (94):181 -183. 
Suarez -Fueyo A, et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine 
response followed by regulatory T -cell generation. J Allergy Clin Immunol, 2014. 133(1): p. 
130-8 e1-2. 
Tabar AI, et al. Double -blind comparative study of cluster and conventional immunotherapy 
schedules with Dermatophagoides pteronyssinus. Journal of Allergy and Clinical Immunology, 
2005. 116(1): p. 109 -118. 
Wagenmann M et al. The time course of the bilateral release of cytokines and mediators after 
unilateral nasal allergen challe nge. Allergy. 2005. 60:1132 -1138.  
Wambre E et al. A phenotypically and functionally distinct human TH2 cell subpopulation is 
associated with allergic disorders. Sci Transl Med. 2017. (9):401, epub Aug 02.  
Wenzel S, et al. Dupilumab efficacy and safety in a dults with uncontrolled persistent asthma 
despite use of medium -to-high-dose inhaled corticosteroids plus a long -acting beta2 agonist: a 
randomised double -blind placebo -controlled pivotal phase 2b dose -ranging trial. Lancet. 2016. 
388(10039): p. 31 -44. 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 85 of 87 
CONFIDENTIAL  23. INVESTIGATOR’S AGREEME NT 
I have read the attached protocol: A Study To Evaluate The Efficacy Of Dupilumab As An 
Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis 
Symptoms Using The Nasal Allergen Challenge Model, and agree to abide by all provisions set 
forth therein.  
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, 
state, or locality relati ng to the conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by any court or 
regulatory agency will not be allowed to conduct or work on studies for the sponsor or a 
partnership in which the spo nsor is involved.  I will immediately disclose it in writing to the 
sponsor if any person who is involved in the study is debarred, or if any proceeding for 
debarment is pending, or, to the best of my knowledge, threatened.  
This document contains confident ial information of the sponsor, which must not be disclosed to 
anyone other than the recipient study staff and members of the IRB/EC.  I agree to ensure that 
this information will not be used for any purpose other than the evaluation or conduct of the 
clinical investigation without the prior written consent of the sponsor.  
   
(Signature of Investigator)   (Date)  
   
(Printed Name)    
 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 86 of 87 
CONFIDENTIAL  APPENDIX  1. TOXICITY GRADING SCA LE FOR GRADING ALLER GIC 
REACTIONS AND ANAPHY LAXIS – COMMON TERMI NOLOGY 
CRITERIA FOR ADVERSE  EVENTS (CTCAE VERSI ON 4.0, 
PUBLISHED 28 M AY 2009; V4.03, 14 J UNE 2010)  
The CTCAE descriptive terminology will be utilized for reporting AEs of allergic reactions and 
anaphylaxis. A grading (severity) scale is provided for each AE term.  
Adverse 
Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 
5 
Allergic 
reaction  Transient flushing or 
rash,  drug fever 
<38 degrees C  
(<100.4  degrees F);  
intervention not 
indicated  Intervention or 
infusion  
interruption 
indicated;  
responds 
promptly to  
symptomatic 
treatment ( eg, 
antihistamines, 
NSAIDS,  
narcotics); 
proph ylactic  
medications 
indicated for  
≤24 hours Prolonged ( eg, not 
rapidly  responsive 
to symptomatic  
medication and/or 
brief  interruption of 
infusion);  
recurrence of 
symptoms  
following initial 
improvement;  
hospitalization 
indicated for  
clinical sequelae 
(eg, renal 
impairment, 
pulmonary  
infiltrates)  Life-
threatening  
consequences; 
urgent  
intervention 
indicated  Death  
Definition: A disorder characterized by an adverse local or general response from exposure to an allergen  
Anaphylaxis  – – Symptomatic 
bronchospasm,  with 
or without urticaria;  
parenteral 
intervention  
indicated; 
allergy -related  
edema/angioedema;  
hypotension  Life-
threatening  
consequences; 
urgent  
intervention 
indicated  Death  
Definition: A disorder characterized by an acute inflammatory reaction resulting from the release of 
histamine and histamine -like substances from mast cells, causing a  hypersensitivity immune response. 
Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of 
consciousness and may lead to  death.  
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Clinical Study Protocol   R668 -ALG -16115 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 87 of 87 
CONFIDENTIAL  SIGNATURE OF SPONSOR ’S RESPONSIBLE OFFIC ERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Team Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the conduct of the study.  
Study Title:  A Study To Evaluate The Efficacy Of Dupilumab As An Adju nct For 
Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using 
The Nasal Allergen Challenge Model  
 
Protocol Number:  R668 -ALG -16115  
Protocol Version:  R668 -ALG -16115 Amendment 2  
 
See appended electronic signature page  
Sponsor’s Responsible Medical/Study Director  
 
 
See appended electronic signature page  
Sponsor’s Responsible Regulatory Liaison  
 
 
See appended electronic signature page  
Sponsor’s Responsible Clinical Study Team Lead  
 
 
See appended electronic signature page  
Sponsor’s Responsible Biostatistician  
 
 
                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
Signature Page for VV-RIM-00062320 v1.0
Signature Page for VV-RIM-00062320 v1.0 ApprovedESig Approval
12-Nov-2018 17:12:34 GMT+0000
ESig Approval
12-Nov-2018 18:28:40 GMT+0000
ESig Approval
ement
13-Nov-2018 13:51:50 GMT+0000
ESig Approval
13-Nov-2018 14:20:21 GMT+0000                                        VV-RIM-00062320-1.0 Approved - 13 Nov 2018 GMT-5:00
